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Pelvic inflammatory disease (PID) is a serious reproductive health issue for women that 
occurs when infection ascends from the lower to the upper genital tract. Possible 
sequalae include infertility, ectopic pregnancy and chronic pelvic pain. The sexually 
transmitted infections (STIs) Chlamydia trachomatis (chlamydia) and Neisseria 
gonorrhoeae (gonorrhoea) are commonly implicated, however the microbial aetiology 
is often unknown. PID diagnosis is imprecise due to its many possible clinical features 
and absence of an objective reliable non-invasive diagnostic test.  As PID epidemiology 
varies between countries and population groups due to different STI prevalence and 
healthcare systems, country specific estimates are critical. 
This thesis aims to improve understanding of the epidemiology of PID diagnosed in 
Australia, particularly with reference to chlamydia infection as this is the most 
frequently diagnosed STI in Australia.  Chapters 1 and 2 discuss the evidence and 
describe what is known about the aetiology and epidemiology and PID, providing the 
rationale for this PhD program of research.   
Chapter 3 involved an analysis of data for 15,690 women aged 16-49 attending a sexual 
health clinic, to examine the microbial characteristics of PID. At a population level, 
chlamydia was the more commonly identified microbial organism, with 8.2% (95% 
Confidence Interval (CI) 7.7, 8.6) of women chlamydia positive, 2.8% (95%CI 2.5, 3.0) 
diagnosed with PID, and, the adjusted population attributable fraction (aPAF) of PID 
associated with chlamydia was 14.1% (95%CI 9.9, 18.0).  Among a subset (n=8,839) of 
women, 0.3% (95%CI 0.2, 0.5) were gonorrhoea positive only, 0.2% (95%CI 0.2, 0.4) were 
gonorrhoea and chlamydia positive, 4.7% (95%CI 4.3, 5.2) were diagnosed with PID, and 
the aPAF for gonorrhoea was 1%.  There was a higher odds of PID for women with 
gonorrhoea or chlamydia (4.4-fold vs 3-fold, respectively) compared with no infection.  
A sub-analysis for asymptomatic women showed that 28% of PID was associated with 
chlamydia but only 0.6% of asymptomatic women were diagnosed with PID.   
Chapter 4 involved a separate comprehensive analysis of the same dataset as in Chapter 
3, to investigate the characteristics of clinically diagnosed PID where no infection was 
identified (pathogen-negative PID). Among 330 women with PID who were tested for 
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chlamydia, gonorrhoea, Mycoplasma genitalium and bacterial vaginosis, 62% had no 
infection diagnosed.  Multivariable logistic regression showed that women with 
pathogen-negative PID were more likely to be aged >30 years (Adjusted Odds Ratio 
(AOR) 1.7, 95%CI 1.0, 3.0) and less likely to have evidence of vaginal inflammation (AOR 
0.5, 95%CI 0.3, 0.9) or report recent unprotected sex (AOR 0.6, 95%CI 0.4, 1.0) than 
women with pathogen-positive PID.   
Chapter 5 investigated PID diagnosis characteristics and time trends at a large sexual 
health clinic, before and after clinical audit feedback.  The study found that between 
2002 and 2016, the yearly PID diagnosis rate increased from 0.8% (37/4836) to 2.9% 
(209/7088) and an increasing proportion of women reported any symptoms (35.7% to 
56.6%) or were diagnosed with an STI or bacterial vaginosis (9.4% to 21.4%).  Univariable 
generalised linear models showed PID rates increased after audit feedback in 2007 by 
8% yearly (incidence rate ratio (IRR) 1.08, 95%CI 1.06, 1.11), but were unchanged (aIRR 
1.01, 95%CI 0.98, 1.03) when patient characteristics were included in multivariable 
analysis.  Since audit feedback, the clinic has reoriented services to increase capacity for 
high risk patients that appear to have had a greater impact on PID diagnosis rates than 
audit feedback.  
Chapter 6 estimated yearly (2009-2014) population rates of PID diagnosis using hospital 
admissions and emergency department data from three Australian states (Victoria, New 
South Wales, Queensland). Zero inflated Poisson regression models were used to 
examine variation in rates by year, age-group and residential area.  In 2014 the overall 
PID rate per 100,000 women aged 15-44 years, was 63.3 (95%CI 60.8, 65.9) for 
admissions and 97.0 (95%CI 93.9, 100.2) for emergency department presentations. 
Comparing 2014 with 2009, the overall PID rate in admissions did not change, but when 
examined by type of PID, admission rates increased for chlamydial and/or gonorrhoeal 
PID (aIRR 1.73, 95%CI 1.31, 2.28) and unspecified PID (aIRR 1.09, 95%CI 1.00, 1.19) but 
declined for chronic PID (aIRR 0.83, 95%CI 0.73, 0.95).  PID rates in emergency 
departments were higher (aIRR 1.34, 95%CI 1.24, 1.45) in 2014 than 2009 and 
substantially higher for women aged 15-24 (aIRR 2.78, 95%CI 2.62, 2.94) than 35-44 
years.   
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In conclusion, this thesis provided the first Australian estimates of the population level 
risk of PID associated with chlamydia and gonorrhoea. This new information based on 
the PAF suggests that eliminating chlamydia in a high prevalence population might only 
reduce PID by 14% and around 1% if gonorrhoea were eliminated.  For low chlamydia 
prevalence populations, the PAF findings suggest that only a small number of PID cases 
might be avoided by widespread chlamydia screening.  This thesis provided updated 
evidence for the frequency of PID pathogens in Australia, and, the many cases without 
an identified pathogen highlighted the need for non-invasive bio-markers for upper 
genital tract inflammation.  In the absence of bio-markers the decision to commence PID 
treatment should continue to be based on clinical features and sexual risk.  This thesis 
found that PID remains a substantial cause of attendances at sexual health clinics and 
hospitalisations for reproductive related health issues for women in Australia. Analyses 
of sexual health clinic data demonstrated the importance of adjustment for patient 
characteristics in interpreting time trends, and, investigation of hospital data showed 
how ecological analyses of data from health settings where women with PID are 
managed can be used to measure PID trends.  Evidence was provided for an increase in 
PID diagnosed in Australian emergency departments that could reflect increasing PID 
incidence, shifting healthcare usage from primary care, or, inadequacies in PID diagnosis 
and management in primary care.   Primary care data and systems to monitor PID 
incidence are needed to better understand PID epidemiology, healthcare usage, and the 
impact of chlamydia and STI control policies.     
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Chapter 1:  Introduction 
1.1 Background  
1.1.1 Pelvic inflammatory disease and its epidemiology- an overview 
Pelvic inflammatory disease (PID) is a clinical condition involving inflammation of the 
structures of the female upper genital tract.  PID generally occurs as an acute infection of less 
than 30 days duration that follows ascension of micro-organisms from the vagina or cervix.1-
4  PID is a serious reproductive health issue for women, that can cause inflammation and 
scarring of the fallopian tubes that can lead to tubal factor infertility, ectopic pregnancy, or 
chronic pelvic pain.4-6   
The sexually transmitted infections (STIs) Chlamydia trachomatis (chlamydia) and Neisseria 
gonorrhoeae (gonorrhoea)7 are long established causes of PID.  Other pathogens that have 
been associated with PID include  Mycoplasma genitalium,8 9 bacterial vaginosis,10 
Trichomonas Vaginalis,11 and enteric and respiratory pathogens.2 Another physiological 
pathway for developing PID has been observed when Mycobacterium tuberculosis or 
actinomyces species have infected the pelvis via the lymphatic system or blood.2  
The clinical picture of acute PID (referring to ascending infection of recent onset) varies 
widely.  Acute PID can be mild to moderate in severity, the key feature being bilateral recent 
onset lower abdominal or pelvic pain that can be accompanied by abnormal vaginal discharge, 
intermenstrual bleeding or dyspareunia.2 6 12 Severe PID involves a systemic response with 
features such as fever, nausea and vomiting or severe pain and abdominal guarding related 
to peritonitis.6 12 Some women experience no signs or symptoms as infection ascends to the 
upper genital tract to cause sub-clinical PID.2 6 Depending on severity, diagnosis and 
management of acute PID can occur in ambulatory or inpatient settings.12 13 The term PID is 
also used to refer to chronic upper genital tract inflammation, that is classified in hospital 
admissions as chronic salpingitis and oophoritis, or, chronic inflammatory diseases of the 
uterus. In hospital data, PID is also frequently classified as PID of unspecified duration.14 15  




Box 1: Definition of PID for this thesis 
The term PID in this thesis, will refer to upper genital tract inflammation arising from 
ascending infection from the lower genital tract.  Sub-clinical PID is encompassed by this 
definition.  However, this thesis will analyse routinely collected data sources in which a PID 
diagnosis is based on the clinical presentation and assessment, therefore sub-clinical PID 
cases are unlikely to be identified in these data. This thesis will analyse data from two 
routinely collected sources (sexual health clinic attendances and hospitalisations).  The 
term PID in this thesis will also refer to unspecified PID or chronic PID that is often 
represented in hospital data sources.   
For women with PID, timely diagnosis and effective antimicrobial management is important 
to reduce the risk of progression to infertility or other sequelae.  Most PID diagnoses are 
clinically made and with a wide range of possible manifestations it is difficult to diagnose.(6, 
13, 14) There is no objective, non-invasive diagnostic test or combination of signs and 
symptoms that are both sensitive and specific to a PID diagnosis.6 12  Diagnostic certainty (i.e. 
specificity) is greater when a number of clinical features are combined to reach a PID diagnosis 
but comes at the expense of sensitivity thereby reducing the number of women with PID who 
are identified.13 16 In order to minimise the number of PID cases that are missed, guidelines 
recommend a low threshold for initiating PID treatment, the minimum diagnostic criteria 
being any one of uterine, cervical motion or adnexal tenderness in sexually active women 
with recent onset pelvic pain where no other cause is identified.13  
Due to its often poly-microbial nature, PID is treated with antibiotics to cover the likely 
pathogens. However, the proportion of PID cases caused by pathogens, for example 
Chlamydia trachomatis will depend on the underlying prevalence that will vary between risk 
groups, geographic areas and health settings. Past studies have reported detection of 
chlamydia in 14% to 65% of laparoscopically diagnosed PID in a range of health settings and 
countries4 and gonorrhoea in 14% of laparoscopically diagnosed PID in the United Kingdom 
(UK).17 Many studies of PID aetiology have been hampered by small sample size. More 
recently, gonorrhoea and chlamydia were detected in 4.4% and 10% respectively of women 
with clinically diagnosed PID in emergency departments in the United States of America 
(US).18 Up to two thirds of PID cases may have no aetiological agent detected.19  
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PID and its sequelae account for substantial health care costs20 and their prevention is an 
important reason for STI control policies.21 22  Many high-income countries have introduced 
programs for opportunistic chlamydia testing23 24 and the UK has implemented systematic 
chlamydia screening for young sexually active persons.25 In consideration that outcomes such 
as infertility may not be recognised until affected women try to conceive, PID has been used 
as an interim outcome for monitoring the relationship between STIs and more distant adverse 
outcomes.22  
At an individual level, the risk factors for PID are largely those for STI acquisition; younger age, 
multiple sexual partners, recent partner change, inconsistent use of barrier contraception, 
and a history of an STI or a repeat STI infection.19 26 Other risks include uterine 
instrumentation such as for intra-uterine device (IUD) insertion, although this risk is greatest 
if an STI is present at the time of the procedure.27 Availability of health care for timely STI 
diagnosis and management could contribute to decreased risk of PID.28   
Measuring the distribution, determinants and outcomes of PID is challenging.  These 
challenges stem from the fact that PID diagnosis is inaccurate, the microbial aetiology of many 
cases is unknown, 19 and, depending on clinical severity, women with PID will be represented 
in data from a range of health settings for which the terminology for a PID diagnosis is 
variable.1 6 29-32 Further, few countries have PID surveillance systems, and, measurement of 
PID trends relies largely on ecological analyses of routinely collected data from health settings 
where PID is diagnosed.   
1.1.2 Australian context and rationale 
In Australia, chlamydia is the most commonly notified STI, around 100,000 cases in 2017, and 
is predominantly diagnosed among young heterosexuals.33-35 Gonorrhoea occurs 
predominantly among men who have sex with men (MSM) and heterosexuals in remote 
Aboriginal communities, but notification rates in women more than doubled from 2007-2017 
(7282 cases in women in 2017).33-35 Care for most STIs and complications is provided through 
primary healthcare services that include general practice (Australia’s mainstream primary 
care setting), Aboriginal community controlled health services, family planning and specialist 
sexual health clinics.21   
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Australian STI control policy has a strong focus on opportunistic chlamydia testing with 
objectives to detect and treat asymptomatic infections, reduce transmission and associated 
morbidities, including PID.21 36 Annual or more frequent testing for chlamydia and other STIs 
is recommended for some priority populations, particularly among MSM.21 37 38 
It is essential that we have data to monitor progress against STI policies and to inform future 
policies and programs. PID has been used as an outcome measure in chlamydia screening 
trials internationally,25 39 but there are limited Australian and international data quantifying 
how much PID could be avoided by preventing chlamydia.  Country and population group 
specific estimates of PID are critical to reflect the underlying prevalence of STIs and other risk 
factors, and, accessibility and quality of sexual health care.  Aside from two data linkage 
studies showing the risk of PID hospitalisation was substantially higher after gonorrhoea than 
chlamydia infection and also higher following gonorrhoea or chlamydia compared with no 
infection,40 41 there are no Australian primary care data on PID risk associated with specific 
pathogens.  Further there is no routine surveillance for PID in Australia. Between 1992 and 
2007, a number of studies showed declining PID hospital admission rates in Australia14 24 that 
paralleled a general downward trend observed in many high-income countries.24 42 43 
However more recent data for Australia are needed.   
The challenges in clinically diagnosing PID have been extensively documented13 16 with 
variability in PID diagnosis between clinicians reported in an Australian and a UK sexual health 
clinic.44 45 In the USA, some interventions to improve PID diagnosis46 47 have been modestly 
successful if multifaceted (education, posters of guidelines, written discharge handouts) and 
targeted a range of groups, medical and nursing staff and patients.  Aside from clinical audits 
of PID diagnosis in a sexual health clinic44 and in Aboriginal medical services,48 there has been 
limited assessment of PID diagnosis practices in Australia.  
This PhD will contribute to addressing these gaps in knowledge and generate new and 
updated information about the epidemiology of PID diagnosed in Australia.  Sexual health 
clinic data will form the basis for quantitative assessments of the microbial characteristics of 
PID diagnosed in Australia, and, investigation of PID diagnosis characteristics and time trends 
in the period before and after PID clinical audit feedback.   Quantitative analyses of routinely 
collected Australian hospital data will be conducted to determine updated time trends in 
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rates of PID admissions. Inclusion of emergency department data in time trend analyses, will 
provide new information about PID epidemiology for Australia.  
1.2 Aim of this thesis   
This PhD seeks to improve understanding of the epidemiology of PID diagnosed in Australia, 
particularly with reference to chlamydia infection.  
1.3 Objectives of this thesis    
1. To investigate the microbial organisms associated with PID diagnosed in Australian 
sexual health clinic attendees 
2. To investigate time trends in PID diagnosis in an Australian sexual health clinic  
3. To estimate time trends in PID diagnosis in Australian hospitals 
1.4 Outline of this thesis    
The research undertaken in this thesis seeks to improve our understanding about the 
epidemiology of PID diagnosed in Australia, particularly with reference to chlamydia infection, 
as this is the most frequently diagnosed STI in Australia.  The term PID (Box 1, p2) in this thesis 
refers to acute (mild to moderate, or severe) PID arising from ascending infection from the 
lower genital tract and to chronic and unspecified PID that is often represented in hospital 
admissions data.  Chapter 2 provides a detailed literature review of the aetiology and 
epidemiology of PID in Australia and internationally.  In Chapter 3, the population attributable 
fraction (PAF) of PID associated with a current chlamydia or gonorrhoea infection was 
assessed among over 15 000 sexual health clinic attendees. The results were published in the 
journal Sexually Transmitted Infections in 2016 and provide new information about how much 
PID might be avoided by eliminating these infections. In Chapter 4, these sexual health clinic 
data were further analysed to compare the characteristics of PID cases for which chlamydia, 
gonorrhoea, M. genitalium or bacterial vaginosis were not detected (pathogen negative PID) 
to PID with a pathogen identified. The results were published in the journal Sexually 
Transmitted Infections in 2017.  Chapter 5 focuses on PID diagnosis by sexual health clinic 
doctors.  PID diagnosis characteristics and trends over time before and after clinical audit 
feedback are investigated. A manuscript has been prepared and submitted to the journal 
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Sexual Health and is currently under review.  This is the first study to assess time trends in PID 
diagnosis in an Australia sexual health clinic. In Chapter 6, population rates of PID diagnosis 
in hospital admissions and emergency presentation data across three Australian states 
(Victoria, New South Wales (NSW), Queensland) are presented by year for the period 2009 to 
2014.  Ectopic pregnancy rates using population and live birth denominators are also 
presented.  The results were published in Sexually Transmitted Infections in 2018. Chapters 3 
to 6 also describe the strengths and limitation of using routinely collected data and adopt 
statistical approaches that consider potential biases associated with these data. Chapter 7 
discusses the Chapter findings against the objectives and the challenges faced within this PhD 
topic including PID aetiology and clinical diagnosis, issues related to availability of data to 
investigate PID epidemiology, and analytical challenges associated with routinely collected 




Chapter 2:  Literature review 
2.1 Pelvic inflammatory disease 
2.1.1 Definition of pelvic inflammatory disease 
The term PID encompasses a spectrum of inflammatory disorders of the female upper genital 
tract (endometrium, fallopian tubes, ovaries, pelvic peritoneum).  PID generally occurs as an 
acute infection of less than 30 days duration that ascends from the lower genital tract through 
the cervix to cause endometritis (infection and inflammation of the uterine lining) that then 
spreads to the fallopian tubes to cause salpingitis (Figure 1).1-4 12 The terms endometritis and 
salpingitis have been used to refer to PID.  PID is a serious reproductive health issue for 
women, that can cause inflammation and scarring of the fallopian tubes that in turn can lead 
to tubal factor infertility, ectopic pregnancy or chronic pelvic pain.4-6 Another physiological 
pathway that has been observed for PID is when Mycobacterium tuberculosis or actinomyces 
species have infected the pelvis via the lymphatic system or blood.2  
As noted in Section 1.1.1, the clinical picture of acute PID varies and can include sub-clinical 
PID, mild to moderate PID,  and severe PID.2 6 12 Depending on severity, diagnosis and 
management of acute PID can occur in ambulatory or inpatient settings.12 13 The term PID is 
also used to refer to chronic upper genital tract inflammation, that is classified in hospital 
admissions as chronic salpingitis and oophoritis or chronic inflammatory diseases of the 
uterus. In hospital data, PID is also frequently classified as PID of unspecified duration.14 15  
The term PID (Box 1, p2) in this thesis will refer to acute (mild to moderate, or severe) PID 
arising from ascending infection from the lower genital tract and to chronic and unspecified 
PID that is often represented in hospital admissions data.   
The majority of PID cases are thought to be caused by STIs that have ascended from the vagina 
or cervix,1 2 and include chlamydia, gonorrhoea,7 and M. genitalium.8 9 PID can be 
polymicrobial49 and associations between bacterial vaginosis10 and a range of enteric and 





Reprinted from Medicine 42(6) Ross J, Pelvic Inflammatory Disease, Page 334. Copyright (2014), with permission from Elsevier. 
Figure 1 Pathogenesis of pelvic inflammatory disease 
2.1.2 Aetiology of pelvic inflammatory disease 
The aetiology of PID is complex.  A relationship between gonorrhoea, PID and infertility was 
recognised in the late 19th century.7 51 Tubo-ovarian abscess and tubal obstruction were 
common during the gonorrhoea epidemics in the 1960s to 1980s.52 Much of our knowledge 
about PID aetiology stems from epidemiological, clinical, laboratory and experimental studies 
conducted in the latter half of the twentieth century.1 Laparoscopy based studies during the 
1970s to 1990s enabled diagnosis of salpingitis via visualisation of erythema, oedema or 
exudate of the fallopian tubes in women with suspected PID and facilitated understanding of 
PID pathogens.7  Although sample sizes for some studies were small, these laparoscopically 
based studies, showed that clinical diagnosis of PID is imprecise, with only around two-thirds 
of women with clinically diagnosed PID had evidence of salpingitis on laparoscopy.7  PID 
research during this period highlighted the poly-microbial nature of PID with isolation of 
gonorrhoea, chlamydia and anaerobic micro-organisms from the fallopian tubes of women 
with salpingitis.53 The term silent PID or silent salpingitis was coined to apply to the tubal 
damage experienced by many women but without the clinical symptoms of PID. Tubal biopsy 
specimens for infertile women with a history of PID and for infertile women without a history 
of PID have shown similar morphologic damage including flattened mucosa and reduced 
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ciliary beat frequency that for both groups was strongly associated with evidence of past 
chlamydia infection.54 The mechanism for ascent of pathogens to the upper genital tract is 
still not entirely understood. It occurs via canalicular spread of pathogens from the lower 
genital tract to the upper genital tract.1 55 There are a range of factors that may facilitate or 
hinder pathogen ascent to the upper genital tract including the vaginal microbiome, vaginal 
pH, cervical mucous, female sexual hormones, the endocervical epithelium, cervical ectopy, 
and other factors. 56-61 For younger women, many of these factors combine to create a higher 
risk of PID.28  These factors in pathogen ascent are described in more detail below. 
The vaginal microbiome and vaginal pH 
The normal healthy vaginal microbiome comprises a mix of microorganisms that changes 
through a woman’s lifetime.  For women of reproductive age, Lactobacillus sp., predominate 
and have long been recognised as playing a protective role against infection ascent to the 
upper genital tract.  Lactobacillus sp. produce lactic acid that helps to maintain vaginal pH at 
or below 4.5, thereby inhibiting growth of non-indigenous aerobic and anaerobic organisms 
and subsequent ascending infection.56 This healthy mix of vaginal flora is susceptible to many 
influences.  If disrupted it can result in an elevated pH and bacterial vaginosis that is 
characterised by an overgrowth of anaerobes or other microbes57 and increased risk of 
chlamydia and gonorrhoea infection58 and subsequent ascent of micro-organisms to the 
upper genital tract.    
During the 21st century molecular based techniques have been increasingly used to study the 
human microbiome in health and disease, including the female reproductive tract.62-64 These 
studies have facilitated a deeper understanding of the complexity of the vaginal microbiota 
and the associated risk of urogenital infection.  For asymptomatic reproductive age women, 
five main bacterial communities or community state types (CSTs) of the healthy vaginal 
microbiota have been identified. Four are dominated by Lactobacillus sp., L. iners (CST I), L. 
crispatus (CST II), L. gasseri (CST III), L. jenseni (CST V), and, the fifth (CST IV) has lower 
proportions of Lactobacillus sp., higher vaginal pH, and higher proportions of anaerobic 
organisms including bacterial vaginosis associated bacteria. Vaginal pH and the proportions 
of each CST have also been found to vary between different ethnic groups.65 66  
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The composition of some bacterial communities can vary markedly over time.  Factors 
associated with instability include menstruation, pregnancy and sexual activity but are poorly 
understood.  L. crispatus, and L. gasseri dominated communities seem the most consistent, 
with transitions to another CST largely associated with menstruation before reverting to the 
usual CST.67 L. Iners dominated and low Lactobacillus sp. communities are less stable, with 
transitions from L. iners to a low Lactobacillus sp. community observed.67 Importantly, women 
with low vaginal Lactobacillus sp. whilst often asymptomatic for bacterial vaginosis are at risk 
of urogenital infections.68 Associations for chlamydia infection with both L. iners dominated 
and low Lactobacillus sp. communities have been reported69 and in-vitro studies of cervical 
epithelial cells have shown that different types of lactic acid from Lactobacillus sp. are 
associated with protection against chlamydia infection that is dependent on pH level.70 In 
general, it appears that more diverse vaginal microbiota are less resilient to disturbance and 
at increased risk of disease.69  
Cervical mucous and female sexual hormones  
The cervix acts as a natural barrier to pathogens entering the endometrial cavity via 
downward flow of mucous and the cervical mucous plug.  During the menstrual cycle the 
cervical mucous varies in viscosity depending on the phase of the cycle.59 60 In the follicular 
phase (beginning the first day of menstrual bleeding), oestrogen production increases until 
oestrogen levels are highest around two weeks later when ovulation occurs (the ovulatory 
phase).71  As oestrogen levels increase, the cervical mucous decreases in viscosity and 
becomes watery to facilitate movement of spermatozoa. Following ovulation, is the luteal 
phase that ends just before menstruation, unless fertilisation occurs.  During the luteal phase, 
progesterone levels gradually increase and the cervical mucous becomes thicker and highly 
viscous, acting as a barrier to advancement of spermatozoa.71  Hence, pathogens may be 
more likely to ascend to the upper genital tract when oestrogen levels are high in the follicular 
phase than in the luteal phase when progesterone is the dominant hormone.  Some evidence 
to support this comes from a study of 104 women with salpingitis; in which women with an 
associated gonorrhoea or chlamydia infection were more likely to have PID symptoms 
commence within the first seven days of the menstrual cycle compared to women with non-
chlamydial, non-gonococcal  salpingitis.72  
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The use of oral contraceptives has been thought to offer some protection against ascending 
infection. Studies from the 1980s and 1990s have reported lower rates of symptomatic 
chlamydial PID for women using oral contraceptives compared for women with a chlamydia 
infection and not using oral contraceptives.73 74 Another explanation for this finding was that 
oral contraception may decrease the severity of the symptoms of upper genital tract 
inflammation, thereby being associated with a greater risk of sub-clinical PID.75 For women 
with gonorrhoea infection, this protective association between oral contraception and PID 
has not been observed.73 More recent studies have shown no difference for oral 
contraception users76 or a greater risk of endometrial chlamydia infection for oral 
contraception users in multivariable models adjusting for other STIs and sexual activity.77 Such 
conflicting evidence has been postulated to occur because earlier studies showing reduced 
PID risk with oral contraception use were based on higher hormonal doses than more recent 
studies.3 Some explanation for increased ascension in oral contraception users comes from 
invitro and animal studies, showing increased chlamydial attachment to human endometrial 
cells with oestrogen,78 and increased chlamydia ascension and upper genital tract pathology 
with oestrogen and progesterone treatment.79 
Endocervical epithelium and cervical ectopy  
Cervical ectopy occurs when the columnar epithelium of the cervical canal extends beyond 
the endocervix into the vagina.  The presence of cervical ectopy is related to oestrogen levels 
and is more common in adolescent women, pregnant women and women taking hormonal 
contraception.61 Cervical ectopy results in a larger area of columnar epithelium that is thinner 
than the normal squamous epithelium of the vagina and has been hypothesised to increase 
susceptibility to STIs thereby contributing to higher PID rates.28 75 Higher chlamydia rates have 
been reported in women with cervical ectopy than for women without ectopy. A study of over 
200 young female UK genito-urinary medicine clinic attendees reported a chlamydia diagnosis 
in 37.4% of women with ectopy compared to 21.8% without,80 and, in 700 young sexually 
active South African women a chlamydia diagnosis was more likely (AOR 1.78, p=0.033) for 
women with cervical ectopy than without.81 Furthermore, young South African women (aged 




PID can also follow procedures that interrupt the cervical barrier such as for IUD insertion, 
surgical termination of pregnancy or hysteroscopy (see also Section 2.3).4 82-85 Concern about 
the safety of IUDs, particularly during the 1960s86 and 1970s (being a period when PID rates 
were high), led to a large number of case control studies that investigated and reported 
associations between the IUD and PID.  However, the same magnitude of risk in prospective 
studies was not observed. Debate about the biases in case control studies (such as over-
diagnosis of PID in women with an IUD insitu) led to systematic reviews on the relationship 
between PID and IUDs.27 87 While uterine instrumentation can increase the risk of PID, this 
risk is higher for women with an STI and limited to around three weeks post procedure.27 82 88   
Other possible factors in PID aetiology include spermatozoa and smoking.  Spermatozoa with 
attached chlamydia have been detected in the peritoneal fluid of women with salpingitis 
suggesting they have acted as a vector to the upper genital tract.89 Associations between 
cigarette smoking and PID have been reported. A case control study in the USA, reported a 
relative risk of 1.7 (95%CI: 1.1, 2.5) of hospitalisation for PID among current smokers 
compared to controls with a non-gynaecologic condition, however , a dose response 
relationship was not observed90 and this finding has not been consistently reported.19 87 91 
While it has been postulated that smoking may affect the immune response or oestrogen 
activity, thereby increasing risk of PID, it is possible that other factors such as being in a lower 
socio-economic group where rates of smoking, STIs and health seeking behaviour are 
different could influence this finding.4 28 
2.1.3 Clinical manifestations  
The key feature of mild to moderate PID is recent onset (less than 30 days duration) of 
bilateral lower abdominal or pelvic pain. Other features may include mucopurulent cervical 
discharge, intermenstrual bleeding, dyspareunia, or, presence of any one of cervical motion 
tenderness, adnexal tenderness or uterine tenderness detected on bimanual examination.2 6 
12 13 Most mild to moderate PID cases can be managed in ambulatory care settings,13 and is 
estimated to represent around a third of PID cases.6 Different pathogens can be associated 
with different clinical features.  Women with chlamydial PID may experience mild or no 
symptoms, however tubal damage appears to be more severe and is thought to occur as part 
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of the immune response to the infection (see also Section 2.2.1).6 92 In contrast, gonorrhoeal 
PID often involves an acute onset of abdominal pain and a direct infection of the epithelial 
lining of the fallopian tube leading to tubal damage.6 12   
Around 5-10% of women with overt PID symptoms will have severe PID.6 The clinical 
presentation of severe PID can include systemic features such as fever, nausea, vomiting, and 
signs of peritonitis such as abdominal guarding. Severe PID is often associated with 
gonorrhoea infection and managed on an in-patient basis. Other features may include an 
elevated white blood cell count, erythrocyte sedimentation rate and C-reactive protein. Some 
women will also develop right-upper-quadrant pain associated with peri-hepatitis (also 
termed Fitzhugh-Curtis syndrome) and tubo-ovarian abscess can occur.6 12 Fitzhugh-Curtis 
syndrome was identified in 4% of young US women with mild to moderately severe PID that 
involved chlamydia as the most common PID pathogen.93 
Many women experience no signs or symptoms as infection ascends to the upper genital tract 
to cause sub-clinical (or silent) PID or silent salpingitis.2 6  Despite the absence of symptoms, 
tubal damage can occur and past chlamydial infection (based on serum chlamydia antibodies) 
has been reported in up to 79% of women undergoing infertility investigations,92 94 with 69% 
of women with tubal infertility having no history of PID.92   As noted earlier (Section 2.1.2), 
similar findings of tubal damage as observed on biopsy and evidence of past chlamydia 
infection have been found for infertile women with a history of PID and for infertile women 
without a history of PID.54 However, while a Swedish study also found that 69% of women 
with tubal factor infertility reported no history of PID, another finding was that only 11% of 
women with tubal pathology reported never having had abdominal or pelvic pain.95 The 
findings from this study suggest that many PID cases that cause reproductive damage are 
undiagnosed rather than being completely asymptomatic.  
2.2 PID pathogens 
Knowledge of the pathogens involved in PID is critical so that anti-microbial therapy can target 
the likely pathogen, for clinicians to know the risks of PID associated with a pathogen, and to 
inform public health responses to PID and STIs. There are still evidence gaps regarding PID 
pathogens.96  The STIs, chlamydia, gonorrhoea,7 M. genitalium 8 9 are known PID causes and 
a range of bacteria, many endogenous to the vaginal microbiota or occurring in increased 
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concentrations with bacterial vaginosis have been isolated from the upper genital tract of 
women with PID.10 50 97  Enteric, respiratory, and novel bacteria have also been identified.1 2 49 
50 97-99 The role of many of these microbes in PID aetiology is unknown. 
The proportion of PID cases caused by different pathogens will vary between country, health 
setting and risk group, depending on the underlying prevalence in the population.  The 
method of PID diagnosis (e.g. clinical versus laparoscopic) and study sample size will also 
influence the proportions of pathogens identified. In US and European based studies during 
the 1970s to 1990s, chlamydia was detected in 14-65% of laparoscopically diagnosed PID 
cases.4 In the US, baseline findings from the Pelvic Inflammatory Disease Evaluation and 
Clinical Health (PEACH) study reported that 40% of women with clinically diagnosed PID had 
a chlamydia and /or gonorrhoea infection100 with M. genitalium detected in 15% of a 
subset.101 Another US study during the 2000s identified chlamydia in 10%, gonorrhoea in 4.4% 
and chlamydia and gonorrhoea coinfection in 2.6% of women with clinically diagnosed PID.18 
Up to two-thirds of PID cases may have no infection identified.19 For Australia, there are 
limited reports about PID pathogens.  A case control study among sexual health clinic 
attendees between 2002 and 2006 identified chlamydia in 19.5% of women with a PID 
diagnosis.44  
This Section will cover the sexually transmitted pathogens, Chlamydia trachomatis, Neisseria 
gonorrhoeae and M. genitalium. It will also cover bacterial vaginosis due to the strong 
association with PID and the importance of the vaginal microbiota with bacterial vaginosis 
and PID aetiology.  Although endemic in some Aboriginal and Torres Strait Islander 
populations,21 T. vaginalis will not be covered, due to infrequent reported associations for 
upper genital tract infection,11 due to this infection not being notifiable in most Australian 
states and Territories(21) and to its infrequent diagnosis in women in general in Australia.102 
Detail of recent patterns in chlamydia and gonorrhoea diagnoses for Australia is provided in 
Section 2.5.2. 
2.2.1 Chlamydia and PID    
Chlamydia trachomatis is a gram-negative bacterium that can be classified into 15 serovars, 
distinguishable by differences in the major outer membrane protein. The incubation period 
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is typically around 5 to 10 days.103 104    Serovars A to C are associated with trachoma and 
serovars L1, L2, L3 cause lymphogranuloma venereum. Serovars D to K cause urogenital 
infections by infecting the columnar epithelium of the lower genital tract from where they 
can ascend to the upper genital tract to cause PID in women or epididymitis in men, and, can 
also infect respiratory and ocular tissues.103 104   Chlamydia can also be transmitted vertically 
from mother to newborn during a vaginal delivery. 103 104    Serovars D, E, F account for up to 
67% of genital infections in women and 75% of genital infections in men and can be 
transmitted by oral, vaginal or anal sex.103-105   
Diagnosis of chlamydia infection is generally based on nucleic acid amplification tests (NAATs). 
For  women these are conducted on cervical or vaginal swabs or urine specimens and are 
highly sensitive to C. trachomatis.13 Prior to NAATs, chlamydia diagnosis was based on culture 
or enzyme immunoassays, for which diagnostic sensitivity is lower.106 107 
Most chlamydia infections are asymptomatic, with some reports of up to 85-90% for women 
and men108 and other reports suggesting that around three-quarters of incident infections for 
women109 and around one-half of incident infections for men are asymptomatic.110 However 
clinical examination has shown that around a third of women with asymptomatic infection 
have local signs of infection, the most common being mucopurulent cervical discharge or 
hypertrophic cervical ectopy.108 Symptoms of female lower genital tract infection can include 
changes in vaginal discharge, dysuria, postcoital or intermenstrual bleeding.105  Women with 
chlamydial PID are often asymptomatic or have a clinically milder disease than gonorrhoeal 
PID. However tubal damage can be more severe than for gonorrhoeal infection and occurs 
secondary to the immune response to infection.1 105 111  
The natural course of chlamydia infection in humans is varied. Without treatment, some 
infections will resolve spontaneously, others will persist over long periods without 
complication and others will progress to complications112-114  Figure 2 shows the relationship 
between chlamydia infection and possible progression to sequalae for woman.115 Quantifying 
the natural history of chlamydia is difficult. It is not possible to know the timepoint when an 
infection was acquired, diagnosed infections are generally treated, and, in studies that have 
followed untreated infections it is often uncertain whether repeat positive tests represent 
infection persistence or reinfection after clearance of an infection.113  Other methodological 
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issues have included small numbers of participants or non-generalisable findings from studies 
undertaken in high prevalence populations.  Available evidence has shown that clearance of 
untreated chlamydia infections increases over time, with around one half of infections 
spontaneously clearing within a year, and, a small amount of infections persisting for up to 
four years.112-114 A recent synthesis of evidence explained the heterogeneity in studies of 
chlamydia duration by distinguishing between prevalent (detected via screening) and incident 
(detected in clinics) infections, and, reported the mean duration of chlamydial infection in 
women (including symptomatic and asymptomatic infections) to be 1.03 years.109  Different 
chlamydia serovars have been found to be associated with different serological responses in 
urogenital infection for women and men,116 and to have different associations with symptoms 
for women.117 Chlamydia clearance rates have been shown to vary by serovar, and, to be 
slower for younger woman,112 although older women may have had past exposure to 
chlamydia.  
 
Reprinted from Lancet Infectious Diseases, 17(8), Unemo M, Bradshaw CS, Hocking JS, et al. Sexually transmitted infections: 
challenges ahead, 11., Copyright (2017), with permission from Elsevier.  
Figure 2 Natural history and sequelae of Chlamydia trachomatis infection in women 
Risk of pelvic inflammatory disease associated with chlamydia infection  
The reasons that some chlamydia infections ascend to the upper genital tract and others do 
not are not fully understood, but appear to be due to a combination of factors.111  Pathogen 
load appears to be associated with the propensity for chlamydia infections to ascend, with 
high chlamydial antibody titres in some studies associated with chlamydial PID49 or severe 
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tubal damage.118 Analyses of data from the PEACH study showed that higher chlamydial 
antibody titres were associated with higher recurrent PID and reduced pregnancy rates for 
women with mild to moderate PID.119  
Repeated chlamydial infection is important.  Higher rates of PID and other reproductive 
sequelae have been shown with repeat chlamydial infections.  A retrospective cohort among 
11,000 women in the US, found a PID diagnosis was more likely for women who had two or 
more chlamydia diagnoses and that higher ectopic pregnancy rates were associated with 
more than one chlamydia diagnosis. Although, in this study, it is possible that clinicians were 
more likely to diagnose PID for woman with repeated chlamydia infection.120 The PEACH 
study, found higher rates of self-reported PID recurrence, chronic pelvic pain and infertility 
were associated with less condom use,121 suggesting repeated exposure to chlamydia 
infection.  A population-based cohort in Denmark (1995 to 2012) found that compared to a 
negative chlamydia test, the risk of a PID diagnosis in hospital (inpatient, outpatient or 
emergency department) was 50% higher for women with one or more positive test and 67% 
lower in women who had never been tested.  A repeat chlamydia diagnosis was associated 
with a 20% higher risk of PID.122  It is not clear if the PID risk is increased because of a longer 
cumulative time of being infected or whether the risk increases with each additional 
infection.22 
Although chlamydia infection is known to cause PID, infertility and ectopic pregnancy, 
difficulties in conducting natural history studies mean that estimates of the incidence for 
these sequalae are limited. Several prospective observational123-128 and controlled trials39 129-
131 have examined the risk of PID after untreated chlamydia infection. A retrospective cohort 
also assessed the risk of PID after chlamydia testing in a hospital emergency department or 
obstetrics or gynaecology out-patient clinic.132 These studies have varied in design, setting, 
population, size and length of follow up, making interpretation and comparisons difficult.   
A summary of the proportion of PID cases diagnosed in untreated chlamydia cases from 
prospective studies is provided in Table 1.  For high risk populations, PID has been diagnosed 
in the two weeks between testing and treatment for 2–5% of chlamydia infections in STI 
clinics22 124 127 or hospital ambulatory settings132 and up to 13% of chlamydia infections in a 
correctional facility.128 Over 1-3 months, PID rates of 20-30% among women with untreated 
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chlamydia infection have been reported126 133 although generalisability of these findings is 
limited by the small sample size for these studies and by gonorrhoeal coinfection in one study.  
Over 12 months, no PID cases were reported for asymptomatic women with chlamydia 
detected during pre-employment screening,114 however PID was defined by self-report and 
study numbers were small.  The Prevention of Pelvic Infection (POPI) randomised controlled 
trial found that over 10% of untreated chlamydia infections among young female students 
developed into symptomatic PID over 1 year.39 Two reviews22 134 focussing on the risk of PID 
after untreated chlamydia infection summarised the key findings and assessed the validity for 
many of the studies listed in Table 1.  Due to variable rates and validity these reviews could 
not determine an overall estimate and identified the need for further prospective studies on 
the natural history of chlamydia infection and assessing rates of symptomatic PID and other 
reproductive sequelae. Although mathematical modelling has estimated that 22% of 
chlamydia infections will progress to PID.135  
Table 1 Prospective studies assessing PID risk after untreated chlamydia infection  








Rees (1980) 125 Observational STI clinic 
High risk female attendees 
3 months 67 5 (7.5) 
Paavonen (1980) 126 Observational STI clinic 
Asymptomatic female partners of men with 
non-gonoccocal urethritis 
1 month 15 3 (20.0) 
Stamm (1984) 133  Observational  
 
STI Clinic 
Chlamydia positive women (coinfected with 
gonorrhoea) 
7 weeks 20 6 (30.0) 
Rahm (1986)123 Observational Screening (contraception clinic)  
Asymptomatic adolescents 
3 months 109 4 (3.9) 
Hook (1994)127 Observational STI clinic   
High risk asymptomatic young women 
2 weeks 93 3 (3.2) 
Morre (2002) 114  Observational Screening (pre-employment)  
Low risk asymptomatic women 
I year 30 0 
Geisler (2008)124 Observational  STI clinic 
Asymptomatic young women 
2 weeks 115 2 (2) 
Risser (2012)128  Observational Screening (corrections facility clinic) 
Chlamydia or gonorrhoea positive young 
women 
2 weeks 74 10 (13.5) 
Oakeshott (2010) 39 RCT  Screening (students) 
Low risk asymptomatic young women 
1 year 74 7 (9.5) 
 
Recent evidence for the risk of PID following chlamydia infection is provided in a 
comprehensive synthesis and analysis of data from prospective controlled studies109 
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comprising the POPI study,39 two RCTs of chlamydia screening,130 131 and a prospective cohort 
within an STI clinic.125 Using a Bayesian approach, Markov models were developed that 
estimated the PID rate in chlamydia infected women and the probability that incident 
chlamydia will cause PID. These models accounted for the time-period of follow up, 
differences in progression rates to PID for chlamydia positive and chlamydia negative women, 
clearance of chlamydia infection, that chlamydia cases detected through screening have had 
a period of time without developing PID, and for reinfection rates after chlamydia treatment.  
A key finding was that for new chlamydia infections in women, 14.8% will progress to 
symptomatic PID and 17.1% to PID if asymptomatic PID is included.109 A further synthesis and 
modelling of prospective, retrospective and routine data sources estimated that 19.7% of PID 
for women aged 16 to 44 years was attributable to incident chlamydia infection.109 These 
modelled estimates adjusted for under-ascertainment of chlamydia in PID cases in the 
retrospective studies, thereby increasing the PAF from 14.5%.109   
2.2.2 Gonorrhoea and PID 
Neisseria gonorrhoeae is a gram-negative bacterium that causes the STI gonorrhoea. For 
women, N gonorrhoeae can infect the mucous membranes of the lower genital tract including 
the cervix and urethra, and the pharynx, rectum and conjunctiva can also be infected.  The 
incubation period between infection acquisition and development of symptoms for female 
gonoccocal infections has been reported at a median of 9-10 days in a sample of 96 women 
attending a Swedish venereal disease clinic136 and around 13 days in a small sample of US 
women.137 Symptoms may include dysuria, increased vaginal discharge or inter-menstrual 
bleeding, although 85% or more of female infections maybe asymptomatic or symptoms may 
not be recognized until complications such as PID have developed.13 136-138  
Like chlamydia, testing for gonorrhoea in many high-income countries and settings is now 
predominantly conducted using NAATs. For  women, NAATs are conducted on endocervical 
or vaginal swabs or urine specimens and can be simultaneously tested for gonorrhoea and 
chlamydia.13 137 Although NAATS are more sensitive than culture based techniques, the 
collection of specimens for culture and antimicrobial susceptibility testing is critical to inform 
individual patient treatment and to contribute to surveillance systems established to monitor 
trends in antimicrobial sensitivities of gonorrhoea infection.13 21 139 
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The clinical picture of gonorrhoeal PID is often severe, involving acute onset of pelvic pain or 
markers of inflammation (e.g. raised white blood cell count, erythrocyte sedimentation rate 
or C reactive protein) compared with chlamydial or M. genitalium PID.1 12 140 Gonorrhoeal 
infection appears to directly damage the epithelial lining of the fallopian tubes to cause the 
abrupt onset of symptoms, thereby prompting women to seek healthcare earlier than for 
chlamydial PID.7  
Although the relationship between gonorrhoea, PID and infertility has long been recognised7 
51 141 much of the evidence for the natural history of gonorrhoea in women stems from studies 
during the gonorrhoea epidemics of the 1960s to 1980s that suggested up to a fifth of 
gonorrhoeal infections in women may progress to PID.4 7 52 55 137 142 More recently, PID has 
been diagnosed in 13% of chlamydia or gonorrhoea-infected adolescents in the 7–15 days 
between testing and treatment.128 A number of modelling studies have investigated the cost 
effectiveness of gonorrhoea and chlamydia control. In the absence of empirical evidence for 
the progression of gonorrhoea to upper genital tract infection, many have assumed the same 
characteristics or probabilities for gonorrhoea as for chlamydia infection.135 143 144  
2.2.3 Mycoplasma genitalium and PID 
First cultured in 1981 from two men with non-gonococcal urethritis (NGU), Mycoplasma 
genitalium is the smallest known free-living organism that is capable of self-replication.145 146 
There are 16 mycoplasmal species found in humans, with M. genitalium being one of four 
mycoplasmas known to have pathogenic properties.  Because M. genitalium is difficult to 
culture and it cannot be visualised on Gram stain (due to lack of a cell wall), research into its 
pathogenic properties only proliferated after development of polymerase chain reaction 
(PCR) technology and NAATs in the 1990s.  Since then, M. genitalium has been consistently 
associated with NGU, detected in up to 25% of symptomatic men with NGU,146 and, studies 
showing high concordance and the same sequence type between sexual partners provided 
evidence for its sexual transmission.147 148  
For women, M. genitalium has received attention for its associations with cervicitis,149 150 
endometritis,151, PID,152 153 infertility and pre-term delivery,146 although evidence for the 
relationship with upper genital tract infection has been inconsistent.154-156  A prevalence study 
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during the 1990s, reported that M. genitalium was detected by PCR in 39% of vaginal and 21% 
of cervical specimens among female sexual clinic attendees presenting with abnormal 
discharge, although no association with cervicitis was shown on multivariable analysis.155 A 
study based in a US sexual health clinic detected M. genitalium in up to 28% of women with 
cervicitis157.146 In the 2000s, M. genitalium was identified by PCR in 2.1% of women attending 
a Swedish gynaecological outpatient service, and PID was diagnosed in 4.9% of M. genitalium 
cases (excluding M. genitalium and chlamydia coinfections).  Multivariable analysis showed 
cervicitis and PID were independently associated with M. genitalium.158  A recent meta-
analysis159 has shown M. genitalium to be highly prevalent in some population groups 
including a pooled estimate of 15.9 (95%CI 13.5, 18.9) for community based female sex 
workers. Several reviews,146 160 and, a meta-analysis of the association of M. genitalium with 
female genital tract disease have been conducted,9 providing evidence for M. genitalium as a 
PID pathogen.  Expressed as odds ratios, the risk of PID associated with M. genitalium ranged 
from 0.2 in a 1987 study using serological samples161 to 12.3 in a 2003 study using PCR,162 
with a pooled odds ratio of 2.1 (95%CI 1.3, 3.5).9  After exclusion of serological based studies, 
the pooled odds ratio was 2.7 (95%CI 1.6, 4.7). The meta-analysis also reported an association 
for cervicitis (OR 1.7, 95%CI 1.4, 2.0) and infertility (OR 2.4, 95%CI 0.9, 6.3).9  
NAAT diagnostics are now available to test for M. genitalium from many anatomical sites 
including vaginal and endocervical swabs and urine specimens, however their use has been 
largely limited to research or specialised clinical settings where symptomatic patients are 
likely to present.163  In light of evidence for adverse female reproductive impacts, high 
prevalence among high risk populations, and concern about growing antibiotic resistance, 
recent debate has focused on increasing availability of testing for M. genitalium,163 164 
however M. genitalium prevalence in asymptomatic populations is less well known.  In 
Australian primary care clinics, M. genitalium was detected in 2.4% of young female 
attendees.152 The meta-analysis159 referred to above has contributed to knowledge of the 
extent of M. genitalium in asymptomatic populations, reporting a prevalence of <1% for 
pregnant women and asymptomatic clinic patients, and for the general population a 
prevalence of 1.3% in high income countries. M. genitalium prevalence was higher (3.9%) but 
more variable (ranging from 0.8 to 9.1%) in general populations in low to middle income 
countries. Based on these findings, M. genitalium testing for asymptomatic clinic attenders 
22 
 
was considered unjustified.159  However, targeted M. genitalium testing of symptomatic high 
risk women, including with suspected PID, is recommended in many clinical settings.110 165  
2.2.4 Bacterial vaginosis and PID 
Bacterial vaginosis is a clinical syndrome associated with changes in composition of the 
vaginal flora, generally from a lactobacillus dominated environment to one with a 
proliferation of Gardnerella vaginalis, Mycoplasma hominis or anaerobic bacteria. Women 
with bacterial vaginosis may present with general symptoms of vaginal inflammation 
including pain, itching, a burning sensation or an offensive vaginal discharge.63 166 167  
The reasons for this shift in vaginal flora are not fully known, although sexual transmission is 
suggested by the epidemiological associations for this condition. Bacterial vaginosis occurs 
more often among women who report a change of sexual partner, high numbers of lifetime 
sexual partners, young age at sexual debut and there is strong conformity between female 
sexual partners.167-169 Other associations for bacterial vaginosis include douching for 
hygiene170 which is thought to promote loss of lactobacilli, and also smoking, recent antibiotic 
use, and low socio-economic status, although these could be surrogates for other risk 
factors.63  Changes in the vaginal microbiome through the menstrual cycle may also mean 
that women have intervals of increased susceptibility to infection.67  There is some evidence 
to suggest that current use of hormonal contraception, the luteal phase of the menstrual 
cycle, and condom use are protective for bacterial vaginosis.63 167 169   
Bacterial vaginosis is extremely common, with prevalence estimates ranging from 12% for 
Australian women,171 to 29% among North American women,172 173 and over 50% for women 
in sub-Saharan Africa.174  Prevalence is widely variable between different ethnic groups, 
ranging from 23% to 52% between white non-Hispanic and black non-Hispanic women in the 
US,173 most likely associated with different vaginal CSTs in different ethnic groups.65 
Women with bacterial vaginosis are at increased risk for PID and other reproductive tract 
pathology including STI acquisition, cervicitis, spontaneous abortion, pre-term delivery, post-
operative infections and post-partum endometritis.169 173  However a direct causal role for PID 
has not been established.  An important issue with epidemiological and aetiological studies 
of bacterial vaginosis is that there are different definitions of this condition. In clinical settings 
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bacterial vaginosis diagnosis is often based on Amsels criteria that are met if three of the 
following four criteria are present; i) a homogenous thin white vaginal discharge, ii) high 
vaginal pH (> 4.5), iii) a fishy vaginal odour, and iv) presence of clue cells on gram stain and 
microscopy of vaginal smears.57 63 110 175  Alternatively, bacterial vaginosis is diagnosed by 
Nugent scoring in which vaginal smears are gram stained then assigned a score of 0-10 based 
on relative proportions of large gram-positive rods (lactobacilli) and gram negative rods (such 
as Gardnerella) or gram variable rods. A score of 0 to 3 is taken to indicate normal vaginal 
flora, 4 to 6 to indicate a disturbance of flora, and 7–10 as bacterial vaginosis.57 166 167 175 176 
Bacterial vaginosis is often diagnosed in association with PID or acute endometritis166 177-179 
and is associated with incident chlamydial and gonorrhoeal infections.167 180 In other studies 
no association between bacterial vaginosis and incident PID has been found,50 although high 
levels of gram negative anaerobes have been present before or at the time of PID diagnosis, 
independently of gonorrhoea or chlamydial infection.50 97 166 177 Based on these findings, 
anaerobic cover for PID treatment is recommended.  
2.3 PID Risk factors  
Knowledge of factors contributing to a woman’s risk for PID is important for supporting timely 
diagnosis and management, and, to inform prevention and control measures.28  The risk of 
PID is higher for women with a current STI (chlamydia, gonorrhoea, M. genitalium), a history 
of an STI, or repeated infection.19 26 49 PID occurs almost only in women who are sexually active 
and the main risks are largely those for STI acquisition.  Socioeconomic and racial disparities 
in PID rates have been reported and most likely reflect higher STI prevalence among lower 
socio-economic or specific racial groups.7 19 85 181 Availability or limited access to health care 
for timely STI diagnosis and management could also contribute to PID risk.28 High PID rates 
have been reported among young women,128 sex workers,26 non-white North American 
women85and Aboriginal and/or Torres Strait Islander women in remote Australia182 for whom 
high rates of infertility have also been reported.183  
A large body of evidence shows that younger women experience higher PID rates than older 
women184-187 and that age is an independent predictor for PID.19 188 189 This association is 
interrelated with a wide range of demographic, behavioural, physiological, and pathogenic 
factors, some of which have a direct causal relationship and others having an indirect 
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relationship with PID development.28  Younger women are at higher risk of PID and STI 
acquisition than older women due to several physiological characteristics. As noted in Section 
2.1.2, these include lower concentrations of protective chlamydial antibodies, larger cervical 
ectopy zones,61 80 81 and more penetrable cervical mucous.7 Behavioural risk factors for PID 
include young age at sexual debut, multiple sexual partners, recent partner change, and 
inconsistent use of barrier contraception methods,19 85 189-191 although in terms of the PID 
causal pathway these are also risk factors for STI acquisition.28 Consistent condom use among 
women with PID has also been shown to reduce the risk of recurrent PID, chronic pelvic pain 
and infertility.121 The risk of a PID diagnosis is further increased for women who have multiple 
or recurrent chlamydia or gonorrhoea infections diagnosed.40 120 192 
Other risks for PID include uterine instrumentation such as for IUD insertion, dilatation and 
curettage, or surgical termination of pregnancy that can facilitate ascent of micro-organisms 
from the vagina or cervix into the endometrial cavity.4 19 82-85   As noted in section 2.1.2, the 
IUD has been debated for its association with PID, with these associations potentially a barrier 
to more widespread uptake of the IUD. Much of this debate occurred during the 1960’s and 
1970s86 when PID rates were high. Concern about IUDs was also fuelled by a meta-analysis of 
studies published between 1974 and 1990 that reported positive associations between IUD 
use and PID.193 However, many studies at this time used a case control design that could be 
biased by over-diagnosis of PID in women with an IUD insitu.  Other meta-analyses have 
stratified studies by design type. Showing that IUDs do not have the same risk of PID in 
prospective studies as retrospective studies, and, that the risk of PID at the time of IUD 
insertion is higher for women with an STI compared to women without an STI, and, that the 
absolute risk is low irrespective of having an STI and is limited to the three weeks post 
procedure.27 82 87 88 
A role for vaginal douching in PID risk has also been debated, based on many women with PID 
reporting a history of douching.85 194-196 Although recent evidence from prospective studies 
found no difference in the risk of PID for women who do or don’t report douching197 and 
suggested a different temporal relationship – that an offensive vaginal discharge with PID may 
lead to increased douching.  One explanation for the association between smoking and PID 
been that smoking may affect the immune response or oestrogen activity.4 28 Smoking is also 
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associated with an increased risk of ectopic pregnancy and infertility. However, the 
association for smoking could reflect different STI risk and health seeking behaviours in 
different socioeconomic groups. Of course, any risk of PID after uterine instrumentation or 
other factors will also be influenced by the underlying prevalence of STIs in different 
geographic regions and population.84 198   
2.4 Diagnosis and management of PID 
2.4.1 PID diagnosis  
Most PID diagnoses are clinically made, but due to the wide range of possible signs and 
symptoms, it is difficult to diagnose.  There is no non-invasive sensitive and specific test for 
PID, and, women with PID can be asymptomatic or have non-specific symptoms.13 Clinical 
diagnosis of PID relies on information gained from the physical examination, the medical 
history and investigations conducted.  
Recent-onset bilateral low abdominal pain is a key feature but can have many causes and it is 
important that differential diagnoses are excluded.  Some alternative causes of low 
abdominal pain include ectopic pregnancy, appendicitis, urinary tract infection, 
pyelonephritis, and, ovarian pathology such as rupture or torsion.12 13 199 Chronic conditions 
such as endometriosis, dysmenorrhoea or irritable bowel syndrome should also be 
considered. Prompt diagnosis, treatment and clinical review of PID is essential to reduce the 
risk of progression to long-term sequelae, and once emergency differential conditions are 
excluded, PID treatment should be commenced.  The minimum diagnostic criteria being any 
one of uterine, cervical motion or adnexal tenderness on bimanual examination in sexually 
active women with recent onset pelvic pain where no other cause is identified.13 32 200 The 
rationale being that over-diagnosis is better than under-diagnosis as the risks of antibiotics 
are potentially less than from possible sequelae associated with ongoing untreated infection.2 
13   
Laparoscopy has in the past been considered the gold standard for PID diagnosis. It enables 
direct visualisation of the fallopian tubes for diagnosis of salpingitis and supports 
identification of upper genital tract pathogens. However, laparoscopy has high inter-observer 
variability, and, it may not detect endometritis or early inflammation of the fallopian tubes.  
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Furthermore, laparoscopy is invasive and impractical for most clinical settings where mild to 
moderate PID is diagnosed.6 12 13 199   
Gaining an accurate history is essential to support or exclude a PID diagnosis.13 199  The history 
should gain a description of the pain. PID pain is usually recent onset (days to weeks) bilateral 
mild to moderate pain in the lower abdomen that may resemble menstrual pain.  Whereas, 
ectopic pregnancy or appendicitis associated pain is often more acute and unilateral or 
radiates to the right iliac fossa.  Around 5% of PID cases may exhibit right-upper-quadrant 
pain, which could be misdiagnosed as cholecystitis, but indicates peri-hepatic inflammation 
or Fitz-Hugh-Curtis syndrome and women with severe PID may have systemic features 
including fever, nausea and vomiting.  Further questioning of women with suspected PID 
could ascertain if they have experienced dyspareunia, postcoital or intermenstrual bleeding 
or altered vaginal discharge (may suggest cervicitis and PID), and, when symptoms started 
(PID pain often starts after menstruation). The history should also cover contraception, sexual 
and menstrual information to ascertain if a pregnancy is likely, whether a woman is at 
increased risk of an STI such as following a recent change of sex partner, or other information 
such as a recent IUD insertion or procedure involving uterine instrumentation.199  
The clinical assessment should include abdominal palpation and pelvic examination.  
Bimanual pelvic examination is conducted to exclude uterine or adnexal abnormalities, and, 
to assess for adnexal or cervical motion tenderness (also termed cervical excitation) that often 
occur with movement of the cervix when pelvic inflammation is present.  If on bimanual 
examination, cervical motion, uterine or adnexal tenderness are not present, the diagnosis of 
PID should be reappraised. Speculum examination should be conducted to visualise the cervix 
and identify any cervical bleeding, friability, mucopurulent discharge or erythema that 
indicate cervicitis and further support a PID diagnosis.13 110 199   
Investigations for all women with suspected PID should include a pregnancy test to help 
exclude an ectopic pregnancy.13 110 199  High vaginal and/or endocervical swabs, and, also first 
pass urine specimens should be tested for chlamydia and gonorrhoea using NAAT, and, also 
of endocervical swabs for M. genitalium in settings where these tests are available.  
Microscopy, culture and antibiotic sensitivity testing should also be conducted for women 
with a positive gonorrhoea test or cervical mucopurulent discharge.  Assessment of high 
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vaginal swabs can help to diagnose other infections, such as bacterial vaginosis. Most women 
with PID have mucopurulent cervical discharge or presence of leukocytes on microscopic 
evaluation high vaginal swabs. If these are not present a PID diagnosis is unlikely. 
Diagnostic certainty (i.e. specificity) increases with each clinical feature that is present in 
addition to one of the minimum criteria (i.e. uterine tenderness, cervical motion tenderness, 
adnexal tenderness).  Additional criteria to enhance a PID diagnosis include one or more of: 
elevated temperature, cervical friability or mucopurulent discharge, elevated erythrocyte 
sedimentation rate or C-reactive protein, abundant vaginal leukocytes, and a lower genital 
tract chlamydia or gonorrhoea infection.  However, requiring all features to be present comes 
at the expense of diagnostic sensitivity and would reduce the number of cases that are 
identified.13 16 201 202 203 A rapid improvement in symptoms after commencement of antibiotic 
treatment further supports a diagnosis of PID. 
Other investigations can include transvaginal ultrasound or magnetic resonance imaging 
(MRI) to identify tubo-ovarian abscess or thickened fluid filled tubes, endometrial biopsy to 
histologically confirm endometritis, or, Doppler ultrasound204 to detect altered blood flow (or 
hyperaemia) with tubal inflammation.  However, these investigations are variable in their 
sensitivity and specificity202 and are not part of routine practice. MRI is expensive and not 
always available, interpretation of trans-vaginal ultrasound is variable between operators, 
and, endometrial biopsy is invasive and timeframes for reporting of results can delay 
diagnosis.2 12 13 16 
In view of the uncertainties around clinical diagnosis of PID and the risks of sequelae from 
delayed diagnosis and treatment, development of a non-invasive biomarker to identify 
women with upper genital tract inflammation is a research priority.205  Elevated serum levels 
of inflammatory proteins and cytokines have been reported in patients with clinically 
diagnosed PID206 207 and different ribonucleic acid biosignatures (many involved in 
inflammation) have been identified in peripheral blood of a small sample of PID cases208 and 
also in mice,209 however objective tests for clinical are not available.  
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2.4.2 PID management   
In view of the diagnostic challenges and potential consequences of untreated PID, clinical 
guidelines recommend a high suspicion for PID diagnosis and that PID treatment is initiated 
promptly. 13 32 200 PID antibiotic regimens should provide broad spectrum cover for the likely 
pathogens, noting that the importance of different pathogens will vary between geographic 
regions and population groups.  Recommendations for PID treatment advise a regime to cover 
chlamydia infection, and to consider gonorrhoeal infection and anaerobic bacteria (e.g. with 
bacterial vaginosis), and more recently to cover M. genitalium if diagnosed.13 32 200  Although 
several PID antibiotic regimens have been shown to be effective in achieving clinical and 
microbiologic cure, there is limited evidence regarding the optimal regime for avoiding long 
term complications, or the superiority of one regime versus another.13 210-214  
Antibiotic treatment should be commenced immediately that a provisional diagnosis of PID is 
made, without waiting for test results. Whether a woman with PID is managed in hospital or 
as an outpatient will depend on her clinical presentation and the clinician’s judgement. 
Hospital admission should be considered for women when a surgical emergency cannot be 
excluded, for severe illness, tubo-ovarian abscess or pregnancy, poor or no response to 
outpatient treatment, or intolerance to oral therapy.12 13 199 200  
For mild to moderate PID, treatment is generally an outpatient regime of oral antibiotics over 
14 days with use of ceftriaxone to cover suspected or confirmed gonorrhoea.30-32 Australian 
guidelines for PID management in primary care recommend oral doxycycline and 
metronidazole, with single dose intramuscular or intravenous ceftriaxone. Antibiotic 
sensitivity testing can be conducted for gonorrhoea, and, in view of high levels of M. 
genitalium resistance to azithromycin, 215 216 Australian guidelines recommend Moxifloxacin 
for 14 days if M. genitalium is diagnosed for a woman with PID (Table 2).200 However, M. 
genitalium testing in Australia is only routinely available in specialist settings such as sexual 
health clinics.21 For patients who may not adhere to a daily medication regime, azithromycin 
as a single dose immediately and one week later is recommended in lieu of doxycycline.200  
Metronidazole is often the choice for anaerobic cover, but can be poorly tolerated.12 Other 
anaerobic agents (e.g. amoxicillin-clavulanate) may achieve an equivalent microbial cure.214 
Inpatient management, when required consists of intravenous therapy (Table 2) until 
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symptoms and signs improve and then followed by oral therapy to complete 14 days of 
antibiotic treatment.  For women with an IUD; removal (along with contraceptive advice) 
should be considered if they have not improved within 2-3 days.  
Table 2 Antibiotic therapy for PID 
PID type Recommended antibiotic treatment* 
Mild to moderate 
Outpatient treatment 
Ceftriaxone 500mg in 2mL of 1% lignocaine by intra-muscular injection, or 500 mg 
intravenously  
PLUS 
Oral metronidazole 400mg twice daily for 14 days 
PLUS 
Oral doxycycline 100mg twice daily for 14 days 
Severe 
Inpatient treatment 
Ceftriaxone 2g intravenously, daily 
OR 
Cefotaxime 2g intravenously, three times daily 
PLUS 
Azithromycin 500mg intravenously, daily 
PLUS 
Metronidazole 500mg intravenously, twice daily 
* If M. genitalium is confirmed also treat with Moxifloxacin 400mg daily for 14 days 
All women with PID should be given advice about rest and appropriate analgesia if needed, 
and, to avoid unprotected sexual intercourse until both the woman and sexual partner/s have 
completed treatment and follow up.  Advice and education (including written information) 
should also be provided about how PID was acquired, the potential long-term consequences 
and how repeated infections can be prevented.  
All patients should be reviewed within 72 hours to assess their response to treatment.  If a 
woman has persistent symptoms and signs an alternative diagnosis or change in antibiotic 
therapy may be indicated. Further follow up two to four weeks later is recommended to check 
that patients have completed their antibiotics and that sexual partner/s have been tested and 
treated.  The importance of avoiding further infections should also be reiterated.   
2.4.3 Improving diagnosis and management   
Evidence from a range of settings and countries shows that there is capacity for 
improvements in PID diagnosis and management.  In the UK, a survey of general practitioners 
(GPs) found that only a third correctly named two signs and two symptoms of PID, a fifth 
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reported that they usually treated sexual partner/s and 54% named the correct antibiotic 
therapy.217  Other UK studies have found that 34% of women diagnosed with PID in general 
practice received the correct antibiotic treatment218 and in sexual health clinics that PID 
diagnostic acumen differed with clinician experience.45 In the US, analyses of emergency 
department data have shown that around a third of diagnosed PID cases received antibiotic 
treatment that was consistent with Centers for Disease Control (CDC) guidelines.219-221  In 
Australia, a clinical audit of records in remote primary health services found that PID was only 
diagnosed in 11% occasions in which PID symptoms were recorded and was inadequately 
treated if diagnosed.48 Another clinical audit in an Australian sexual health clinic found 
disparate PID diagnostic practices between experienced doctors.44   
Strategies to improve PID diagnosis and management have been infrequently reported, and 
where reported have been largely based in US hospital or outpatient settings and shown 
moderate success.  In paediatric outpatients, a multi-level intervention targeting clinicians 
(treatment algorithm, practice guideline, training) and patients (take home antibiotics, 
written instructions) was followed by a substantial increase in the proportion of PID patients 
receiving an appropriate PID medication (38% at baseline vs 91% postintervention) and in 
patients attending for follow up within 72 hours (10% at baseline vs 43% postintervention).222 
In hospital emergency departments and adolescent clinics, an RCT compared the addition of 
an educational PID selfcare video (targeting patients) to standard care to standard care only. 
The study reported that overall follow up rates at 72 hours were low (24%) but were higher 
for interventions than controls (32% vs. 16%) on univariable analysis. There was no difference 
in medication compliance  between intervention and control participants, but sexual partners 
of those viewing the video were more likely (AOR 3.1; 1.0, 9.4) to be treated than partners in 
the control group.223 Another RCT assessed the impact of a short teaching tool using 
hypothetical scenarios on PID knowledge for emergency department clinicians, and although 
overall PID knowledge was low, clinicians who received the intervention had higher 
knowledge about PID treatment but not about PID diagnosis.46 Another multifaceted 
intervention in a US emergency department targeted medical and nursing staff (educational 
presentations, posters of PID treatment guidelines) and patients (written discharge handout) 
and showed improvements in PID diagnosis, PID treatment, and, sexual history taking for 
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young women presenting with lower abdominal pain.47 Targeting doctors and nurses was 
viewed as critical to the interventions success.   
A 2012 systematic review224 assessed three of these studies,46 222 223 and noted that the 
findings were not generalisable to primary care settings where most mild to moderate PID is 
diagnosed and managed.  Further research recommendations were for investigations that 
measured whether interventions such as shortened clinical management guidelines or 
simplified antibiotic regimens lead to improvements in PID diagnosis and management 
compared to current practice, particularly in primary care settings where there is capacity for 
improvement.  Education and training has been a component of successful multifaceted PID 
focussed interventions.47  
Future implementation of evidence based resources toward improving PID diagnosis and 
management should be complemented by professional support and training for clinicians in 
a range of health settings where women with recent lower abdominal pain may present.21 45 
Low abdominal pain is often the key reason for a woman’s presentation to a clinical setting 
and for clinicians to consider a PID diagnosis.  Resources that provide decision trees for 
assessment of recent onset low abdominal in women of reproductive age and possible 
differential diagnoses have been developed199 and could be a tool in workforce training. There 
is a need for an evidence base for such resources. 
2.5 PID epidemiology 
PID and its sequelae account for substantial health care costs20 and their prevention, in 
particular infertility, is an important reason for STI control policies.21 22  Many developed 
countries have introduced programs for opportunistic chlamydia testing23 24 and the UK has 
implemented systematic chlamydia screening for young sexually active persons.25 In 
consideration that outcomes such as infertility may not be recognised until affected women 
try to conceive, PID has been used as an interim outcome for monitoring the relationship 
between STIs and more distant adverse outcomes.22  
Measuring the epidemiology of PID including its distribution, determinants and outcomes of 
PID is challenging.  These challenges stem from the fact that PID diagnosis is inaccurate, the 
microbial aetiology of many PID cases is unknown, 19 and, that depending on clinical severity, 
women with PID will be represented in data from a range of health settings. For example, 
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mild to moderate PID is often treated on an ambulatory basis in primary care clinics or 
hospital emergency departments and severe PID is often treated on an inpatient basis.1 6 29 30 
31 32  Further, PID is generally not a notifiable disease, few countries have systems for PID 
surveillance, and, measurement of PID trends relies largely on ecological analyses of routinely 
collected data from health settings where PID cases are diagnosed.  These include 
hospitalisations, ambulatory care and infertility data, that may also be complemented by STI 
surveillance data to provide a context of STI trends in a population, and, other clinical data 
for example STI testing data to provide a measure of STI control responses.  
An underlying limitation of any study of PID epidemiology using routinely collected data is the 
uncertainty around PID diagnosis and that it is virtually impossible to assess the validity and 
reliability of this diagnosis.  Another important limitation is that such studies will only reflect 
women with PID who have presented to a clinical setting and who have had PID diagnosed, 
therefore not representing sub-clinical PID cases that are still at risk of progressing to tubal 
damage and infertility.  
2.5.1 PID incidence and prevalence  
During the 1960’s and through to the 1980’s, the gonorrhoea epidemics in some high-income 
countries were associated with increasing rates of PID and followed by increasing ectopic 
pregnancy rates.4 15 225 226 In England and Wales, hospital admission rates in which PID (acute 
or chronic) was the main reason for admission increased between 1966 and 1985 to a high of 
132 per 100,000 women aged 15-44 years, with the highest increases seen for women aged 
15-24 years and around two-thirds of admissions being for acute PID (Figure 3).4 15 225 
Subsequent declines in PID admission rates during the 1990s for England and Wales were 
paralleled by increasing PID diagnoses in general practice suggesting a shift to management 
in primary care.4  Also in Sweden, increasing hospital admissions rates for PID during the 
1970s closely followed high gonorrhoea rates peaking at 11 cases per 1000 women aged 15-




Reproduced from Sexually Transmitted Infections, Simms I, Stephenson JM. 76, pp. 80-87, Copyright notice (2000), with 
permission from BMJ Publishing Group Ltd.  
Figure 3 PID by age group, hospital inpatients England and Wales, 1966-1993/94 
Starting in the 1980s and 1990s, widespread declines in rates of PID hospitalisation have been 
reported for many developed countries that have continued into the 2000s, and, have also 
been found to coincide with declines in primary care rates of PID.14 24 42 43 228-230 Some 
instances of increasing PID rates have been reported, for example between 2005 and 2008 
among 15-24 year old women in the north of New Zealand.184 Admission rates vary widely 
between countries. One study assessing PID trends for the period 1998-2008 across Sweden, 
Denmark, New Zealand and Australia reported PID admission rates that ranged from 37 to 
194 cases per 100,000 women aged 15-39 years during the 2000s.  Australian PID admission 
rates were 89 per 100,000 in 2007.24 In the US, PID admission rates were 140 per 100,000 in 
2001 for women aged 15-44 years.42 A recent commissioned review on sexually transmitted 
diseases presented hospital discharge rates during 1990-2014 for inflammatory diseases of 
female pelvic organs (including PID from any cause) for 13 countries across Europe, America 
and Australia that showed wide variability between countries and general declines to around 




Reprinted from Lancet Infectious Diseases, 17(8), Unemo M, Bradshaw CS, Hocking JS, et al. Sexually transmitted infections: 
challenges ahead, 15., Copyright (2017), with permission from Elsevier.  
Figure 4 Hospital discharge rates for inflammatory disease in female organs 
Trends in PID rates are difficult to interpret and comparisons between countries are 
problematic because of differences in healthcare systems, diagnosis and coding, and the 
underlying prevalence of PID risk factors. Declining hospitalisations have been observed in 
association with increasing chlamydia diagnoses and testing, that might appear to be 
influenced by STI control measures.  However, similar declining trends in PID have been 
observed in high and low chlamydia testing countries.23 24 115 Changing sexual behaviours in 
response to the HIV epidemic have also been hypothesised to have contributed to falls in STI 
and PID rates.229 The PEACH study showed similar outcomes following treatment of mild to 
moderate PID in outpatient compared to inpatient settings.100 It is possible that declines in 
inpatient PID represent a shift in care to ambulatory settings, however declines in admission 
and ambulatory care rates have been reported over similar periods.42 187 228 Several studies 
have shown that PID is diagnosed and managed more frequently in ambulatory care than 
hospital settings, with admitted cases more likely to be severe than those managed in primary 
care. In the UK, PID was diagnosed in 1.7% of general practice encounters for reproductive 
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aged women, and, was extrapolated to represent 165,000 PID cases compared with 21,168 
inpatient and 5735 in genitourinary medicine clinics in the same year - 1992.186 More recently 
in the UK, declining rates of definite / probable PID among reproductive age women attending 
general practice between 2000 and 2011 were reported.  However, on inclusion of possible 
PID cases, rates increased, highlighting the difficulties in diagnostic coding for PID and the 
impact this may have on PID trends.231 Another study based in the US showed that of almost 
770,000 PID cases diagnosed annually between 1995 and 2001, that 91% were diagnosed in 
ambulatory care. Hence highlighting the importance of ambulatory care settings for 
measurement of the PID incidence and for a focus on optimal management of PID where the 
majority of cases are diagnosed and treated.42   
2.5.2 Australian context  
In Australia, chlamydia is the most commonly notified STI and is diagnosed predominantly 
among young heterosexuals. Surveillance data have shown steady increases in chlamydia 
notification rates between 2007 and 2011 (largely due to increased testing) that remained 
stable between 2011 and 2015 then increased again in 2016 and 2017. Around 100,000 
chlamydia cases were notified to Australian Departments of Health in 2017, 73% were in the 
15-29 year age group.33-35    Gonorrhoea infection is predominantly diagnosed among MSM 
and heterosexuals in remote Aboriginal communities, but notification rates in women have 
more than doubled from 2007-2017, reaching a total of 7282 cases among women in 2017, 
and the greatest change being in women in urban areas. 33-35 Australian surveillance data also 
monitor trends in chlamydia and gonorrhoea testing. Medicare is the Australian Government 
funded universal health care system.232 Between 2012 and 2016, the number of Medicare-
rebated chlamydia and gonorrhoea tests in Australia increased by 35% and 64% respectively. 
Although rates of chlamydia and gonorrhoea diagnoses will be influenced by testing patterns, 
analyses of Medicare testing data suggests that recent increase in gonorrhoea notifications 
may be related more to increased transmission and less to increased testing,35 raising 
concerns about potential adverse reproductive impacts for women. 
Care for most STI cases and PID is provided through primary healthcare services that include 
general practice, Aboriginal community controlled health services, sexual health and family 
planning clinics.  In Australia, individuals are able to attend multiple general practice clinics of 
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their choice and are not registered to any one GP.233 General practices are privately owned 
businesses where the costs for an individual’s visit are partially or fully covered by Medicare 
or by other practice incentive schemes.234 General practices are widely available, although 
there are fewer clinics in rural areas than the city.235 Sexual health clinics are less widely 
available than general practice clinics but are publicly funded and provide testing and care for 
large numbers of complex patients or priority populations as well as professional 
development, clinical advice and research.21 Hospitals in Australia include a mix of public 
(government-funded) and private hospitals,236 with public hospital emergency departments 
providing emergency care.237 
Like many other countries, Australia does not have a system for surveillance or routine 
monitoring of PID trends, and, analyses presenting trends for PID and other STI sequelae are 
infrequent.  Two studies have assessed trends in PID hospitalisation rates for the Australian 
state of NSW; showing declining rates per 100,000 15-34 year old women from 165 in 1992 
to 64 in 2001,14 and declining rates per 100,000 15-29 year old women from 58 in 2001 to 44 
in 2010.238 These declines were paralleled by declining ectopic pregnancy hospitalisation rates 
(2001-2008)239 and were in contrast to increasing chlamydia notification rates14 over a similar 
period.  A cross-country analysis presented PID rates for Australia and for other high-income 
countries that have health care systems with universal access. As noted above, Australian PID 
admission rates for women aged 15-39 years were 89 per 100,000 in 2007.24 The one study 
assessing PID trends in Australian primary care, presented data for 1998 to 2003 and reported 
that PID diagnosis rates for 15-34 year old women declined from 39 to 19 per 10,000 patient 
encounters.228  
As noted above, interpretation of these trends is difficult and updated data for Australia are 
needed. The declines in rates of PID diagnosed in admissions and primary care during the 
1990s and 2000s could reflect STI trends at that time.  Gonorrhoeal PID can be more clinically 
severe than chlamydial PID.  Australian data have shown the risk of PID hospitalisation was 
substantially higher following a gonorrhoea infection than a chlamydia infection, although the 
risk of hospitalisation was higher following gonorrhoea or chlamydia compared to no 
infection.40 41 These declines in PID hospitalisations occurred in a period that gonorrhoea 
diagnoses for Australian women were rare, potentially resulting in less severe PID cases 
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requiring hospitalisation. Results from the PEACH study around this time provided evidence 
for management of mild-moderate PID in outpatient settings, hence declining hospital rates 
may also reflect altered treatment regimens.100  Chlamydial PID can be more indolent in 
nature and while it is possible that increased testing coverage led to earlier diagnosis of some 
chlamydia infections thereby limiting progression to PID, it is also possible that there is a large 
reservoir of chlamydial PID that is not diagnosed in the primary care setting.  As noted earlier, 
study of PID rates in UK primary care clinics found that rates of definite and probable PID 
declined between 2000 to 2011, but on inclusion of possible PID case the study found that 
rates increased.231 
2.6 The sequelae of PID  
PID can lead to several long-term complications that can have debilitating and severe impacts.  
The most common is chronic pelvic pain, thought to be due to pelvic adhesions, and defined 
as low abdominal pain lasting at least six months and causing functional disability or requiring 
treatment. Although chronic pelvic pain has other causes (e.g. endometriosis), PID is one of 
the more common gynaecologic conditions reported by women also reporting chronic pelvic 
pain.240  Following PID treatment, 18% of a cohort of Swedish women5 and over a third of 
women in the PEACH study121 241 experienced chronic pelvic pain. A data linkage study in the 
UK followed women who have been hospitalised for PID, finding they were 10 times more 
likely to be admitted for abdominal pain than women admitted for other reasons.242 Previous 
PID episodes appear to increase a woman’s risk of chronic pelvic pain after PID and a range of 
demographic, clinical and behavioural risk factors have been identified.241  The impacts of 
chronic pelvic pain after PID are severe, with affected women reporting reduced physical and 
mental health compared to women without chronic pelvic pain.243 
Infertility or ectopic pregnancy that occur due to fallopian tube scarring are the other serious 
sequelae of PID. Infertility, is defined as when a sexually active woman who is not using 
contraception does not conceive after 12 months.244  Ectopic pregnancy is when a fertilised 
egg implants outside of the uterus, most commonly in the fallopian tubes.245  The relationship 
between PID, tubal infertility and ectopic pregnancy has long been recognised. However, 
quantifying the relationship between PID and these outcomes is difficult because of the non-
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specific nature of a PID diagnosis and the long follow up timeframes necessary to measure 
these outcomes.   
The Lund cohort study followed 2501 women with clinically suspected PID during the 1960s 
to 1980s, and found that 16% of women with salpingitis diagnosed by laparoscope developed 
infertility compared with 2.7% of women without salpingitis.5 Furthermore, a higher ectopic 
pregnancy rate among first pregnancies was found for women with PID compared to those 
without. The PEACH study provides further evidence for these relationships.  During the 1990s 
a total of 831 women aged 14-38 years were randomised to inpatient or outpatient treatment 
for mild to moderate PID in the USA and followed for up for 84 months.  Over a mean of 35 
months, 21% of women experienced recurrent PID episodes, 19% were infertile, <1% 
experienced an ectopic pregnancy, and over a third experienced chronic pelvic pain.  The risk 
of infertility was higher for women experiencing repeated episodes of PID.246 247  
2.7 STI control and PID 
2.7.1 Overview 
Because PID is largely of STI aetiology, its control is largely considered in the context of STI 
epidemiology and control.  STI control strategies, particularly for chlamydia are often 
rationalised by the need to reduce PID incidence and other complications with screening 
debated as an intervention toward this objective.  The rationale being that screening will 
diagnose asymptomatic chlamydia infections that then can be treated and in turn reduce 
progression of chlamydia infections to PID.   
There were an estimated 357 million new cases of curable STIs worldwide in 2012, including 
131 million cases of chlamydia, and 78 million cases of gonorrhoea. These and other STIs 
adversely impact the health and lives of children, adolescents and adults around the world, 
and a global response is a priority.139  
Addressing STIs requires a coordinated and sustained approach that seeks to reduce 
incidence and prevalence of STIs and their associated morbidities.  A mix of primary and 
secondary prevention activities, and, systems for monitoring and evaluation are all essential 
to a coordinated response across the continuum of care (Figure 5).139  The shape of any 
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response and the STIs that are prioritised will vary between countries depending on the 
epidemiological and social context, priority populations, and, availability and quality of health 
and preventive services.  The World Health Organisation in its Global Health Sector Strategy 
on STIs 2016-21 has provided targets around reductions in gonorrhoea and syphilis, but not 
chlamydia because the optimal means to control chlamydia are not known.139  However, in 
view of the high frequency of chlamydia infections in Australia and that asymptomatic 
infections can ascend to the female upper genital tract to cause complications115 248 249 this 
section will largely focus on chlamydia control, with some focus on other infections 
(particularly gonorrhoea) that are relevant to PID and other adverse reproductive tract 
complications.   
 
Reprinted from Global health sector strategy on sexually transmitted infections 2016–2021: Towards ending STIs. World 
Health Organisation; June 2016, Chapter 2 – Framing the strategy, p21., Copyright (2016). Available: 
https://www.who.int/reproductivehealth/publications/rtis/ghss-stis/en/ Accessed November 2018.  
Figure 5 The continuum of sexually transmitted infection services and the cascade 
Primary prevention underlies STI control.  It comprises activities that aim to promote safer 
sexual behaviours that leads to a reduction in the risk of acquiring an STI. Primary prevention 
activities include promotion of safer sex behaviours, consistent and effective condom use, 
access to condoms, and STI related knowledge, that can directly target at-risk individuals such 
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as advice in a healthcare setting, or populations such as through school sexual health 
education or social marketing media campaigns.21 248 250 Primary prevention activities that 
prevent chlamydia will in general be effective in preventing other STIs.  
Secondary prevention comprises case detection and effective case management for people 
who already have an infection.  Some people will have symptomatic infection that is 
diagnosed when they present to a healthcare setting and are tested.  Other people will have 
asymptomatic infection that is identified when they are tested for reasons such as they are a 
sexual partner of someone with a diagnosed STI, or because they are identified as being at 
high risk for infection (Figure 6).115  Testing of asymptomatic persons can be opportunistic 
when a test is offered to asymptomatic people in known risk groups (such as young age, 
reports male to male sex), or, through a screening programme where a defined subpopulation 
considered at increased risk of infection compared to the general population are regularly 
offered testing.248 Case management includes treatment of all diagnosed cases of STIs with 
an effective antimicrobial regime, notification and treatment of sexual partners to prevent 
onward transmission, and potential reinfection or complications, and re-testing to identify 
and treat repeat infections.  These activities should be supported by systems for monitoring 
and evaluation of their uptake and impact and systems for monitoring antimicrobial 
resistance, particularly Neisseria gonorrhoeae.   
 
Reprinted from Lancet Infectious Diseases, 17(8), Unemo M, Bradshaw CS, Hocking JS, et al. Sexually transmitted infections: 
challenges ahead, 11, Copyright (2017), with permission from Elsevier.  
Figure 6 Interventions for the control of chlamydia in a population 
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For chlamydia, several high-income countries have recommended yearly opportunistic 
testing for young sexually active heterosexual women and men with corresponding increases 
in testing and case detection reported.13 23 24 37 251 252 The UK has implemented a national 
chlamydia screening programme for young sexually active persons. Chlamydia screening trials 
have been conducted in Denmark, England, the Netherlands, the US and most recently in 
Australia39 130 131 253-256 in which PID has been used as an outcome measure.  These trials have 
been conducted amid worldwide debate as to whether chlamydia screening is cost-effective 
in terms of reducing chlamydia transmission and PID incidence.257 Chlamydia testing 
programs – both opportunistic or screening – could prevent PID either indirectly if they lead 
to decreased chlamydia prevalance or directly if chlamydia is detected and treated before PID 
develops.  Thereby, the success of direct PID prevention will depend on how long it takes for 
a chlamydia infection to ascend to the upper genital tract,258 which can be within days or 
weeks.259 Further, there is no lasting immunity to chlamydia infection and there are concerns 
that increased testing and treatment could render more people at risk of reinfection and 
thereby increase the risk of PID at population level.260 261  
Lower PID incidence rates have been reported over one year following a single offer of a 
chlamydia test compared to no test when results were pooled in a systematic review.262 
However this reduced risk was less apparent in studies at lower risk of bias39 255 than in other 
studies.130 131 In the Netherlands, a trial of register based chlamydia testing via annual postal 
invitations achieved an initial participation rate of 16% that declined with each invitation.253 
In view of the low uptake and findings of no difference in chlamydia positivity between 
intervention and control areas, ongoing implementation of the program was not 
recommended.253 The POPI study in the UK found that most PID occurred in women who 
tested negative for chlamydia at baseline, suggesting these PID cases were related to incident 
infection and that a single yearly screen might only prevent a small amount of PID.39 Further 
analysis of the POPI data estimated the costs of chlamydia screening for women aged 16-24 
years and living in London during 2009 to be around £4 million to prevent around 400 cases 
of PID that incurred £64,000 in healthcare costs.263  Most recently, the Australian Chlamydia 
Control Effectiveness Pilot (ACCEPt) trial investigating the effect of annual offers of chlamydia 
testing in general practice has concluded,256 and found no evidence to support a reduction in 
chlamydia prevalence associated with the intervention or in rates of PID diagnosed in general 
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practice. However, ACCEPt did find that PID hospitalisation rates were significantly lower in 
intervention than control clusters (24.2 per 10 000 women versus 37.9 per 10 000 women), 
difference (-13.7 per 10 000; 95%CI -26.9, -0.5; aRR 0.6, 95%CI 0.4, 1.0).256   
Although it is likely that chlamydia screening does reduce PID, it is unlikely to be cost-effective 
and the focus of many discussions on chlamydia and STI control is shifting from widespread 
testing to primary prevention and to strengthening case management to prioritise partner 
notification and timely re-testing after treatment to prevent or detect re-infections earlier 
and to reduce complications.115 248  
2.7.2 Australian context  
Recent STI control policies in Australia have had a strong focus on opportunistic testing with 
objectives to detect and treat asymptomatic infections, reduce onward transmission and 
reduce associated morbidities, including PID.21 36 250 Like other high-income countries yearly 
opportunistic chlamydia testing is recommended for young sexually active heterosexual 
women and men. Annual or more frequent STI testing for chlamydia, gonorrhoea and syphilis 
in groups considered to be high risk, for example asymptomatic MSM reporting high risk 
sexual behaviours37 38 also forms a significant component of Australia’s STI control policy.21 
From around 2012, most Australian laboratories have conducted dual chlamydia and 
gonorrhoea testing, in which both tests are automatically performed when a test for either 
chlamydia or gonorrhoea is ordered.35 
Increases in testing have been accompanied by increasing chlamydia diagnoses, although 
recent modelling reported in Australian surveillance reports suggest that less than half of new 
chlamydia infections were diagnosed among 15-29-year-olds in 2016 and around a third of 
people diagnosed with chlamydia are re-tested within six months.34 Increases in gonorrhoea 
testing and diagnoses have also occurred with recent data indicating that heterosexual 
transmission of gonorrhoea transmission is increasing.34 Further, as noted above (Section 
2.7.1) the ACCEPt study found it was not possible to reduce chlamydia prevalence in the 
population with achievable levels of annual testing.  The ACCEPt study also showed sub-
optimal rates of partner notification and retesting after chlamydia treatment.256 264 Other 
Australian evidence shows high rates of repeat chlamydia diagnosis in the year after 





The need for improved case management is identified in Australian policy.  A range of 
interventions to improve partner notification (e.g. partner notification websites)266 and 
retesting (e.g. SMS reminders and mailed specimen kits)267 have been evaluated, however 
mild to moderatetheir widespread uptake is irregular. Priority actions include improving 
access to sexual health care via a strengthened primary care sector, development of methods 
to enhance partner notification and treatment, and, methods to increase re-testing after 
treatment to detect repeat infections early.21 250   
Australian policy identifies PID, and, also ectopic pregnancy and infertility as important STI 
associated morbidities.  Interventions that aim to increase partner notification or uptake of 
re-testing are recommended for their potential to reduce transmission, reinfections and 
complications. However, Australia has no system for monitoring STI-related morbidities and 
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3.1 Introduction  
This Chapter and Chapter 4 address the first objective of this thesis, to investigate the 
microbial associations with PID in Australia.  Chlamydia and gonorrhoea infections are well-
known PID causes, and, PID prevention is a key objective of opportunistic testing or screening 
for these infections.21 22  It is important to know the attribution of these STIs to PID to 
ascertain the potential impact of control activities on this morbidity.  Further, country and 
risk group specific estimates are needed to reflect the underlying prevalence of STIs and other 
risk factors.  A case control study among Australian sexual clinic attendees between 2002 and 
2006 identified chlamydia in 19.5% women with a PID diagnosis.44 Aside from two data linkage 
studies showing that chlamydia or gonorrhoea conferred a higher risk of PID hospitalisation 
than no infection40 41 there are no recent Australian data about PID pathogens.  
This Chapter presents findings from an analysis of routinely collected Australian sexual health 
clinic data.  This analysis was published in Sexually Transmitted Infections268 and presents 
findings for the first estimates based on clinical data of the PAF of chlamydia and gonorrhoea 
for their contribution to PID in Australia.  The PAF takes into consideration both the 
population prevalence of an exposure and the magnitude of the risk of an outcome that is 
associated with the exposure.  The PAF is a measure that can be used by policy makers to 
consider the potential benefits of an intervention.  For example, if chlamydia screening were 
introduced and if chlamydia was eliminated, then, how much PID in the population may be 
avoidable.  Individual-level risk factors for a PID diagnosis were also assessed.  The methods 
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used in this chapter are detailed in the following publication. Multivariable logistic regression 
models were used to adjust individual level and population level estimates for demographic 
and behavioural factors identified a priori as confounders on the causal pathway between 
chlamydia and gonorrhoea infection and PID. Further, because not all women attending the 
clinic were tested for chlamydia or gonorrhoea, a sensitivity analysis using multiple 
imputations for missing test result was conducted.  The findings for the sensitivity analysis 
were published as additional material that was published online only and are provided in 


























3.2 Chapter summary 
This publication reported on 18,586 new female patients to an Australian sexual health clinic; 
among whom 15,690 were tested for chlamydia, 8.2% tested chlamydia positive, 2.8% were 
diagnosed with PID and the aPAF for chlamydia was 14.1%.  Among a subset (n=8,839) of 
women 0.3% were gonorrhoea positive only, 0.2% were gonorrhoea and chlamydia positive, 
4.7% were diagnosed with PID, and the aPAF for gonorrhoea was 1%.   
This new information based on the PAF suggests that for a high chlamydia prevalence clinic 
population, eliminating chlamydia might at most reduce PID by 14% and eliminating 
gonorrhoea might only avoid 1% of PID. A sub-group analysis assessed the PAF of chlamydia 
for PID in asymptomatic women, in recognition that asymptomatic presentation might be 
more common for women attending general practice, being the setting where most 
chlamydia screening would occur if implemented in Australia.  The findings suggested that in 
a setting with low chlamydia prevalence, chlamydia elimination might only prevent a small 
number of PID cases.  The chlamydia PAF for PID (14%) reported in this publication is lower 
than the estimate of 19.7% reported for women aged 16 to 44 years in recent modelling for 
the contribution of chlamydia to PID (see Section 2.2.1).  The modelled estimates were 
adjusted for under-ascertainment of chlamydia in PID cases that can bias retrospective 
studies.109 A limitation of the PAF analysis in this thesis was that the association of chlamydia 
to sub-clinical PID could not be included in PAF estimates.   
The publication reported a 4.4-fold higher odds of a PID diagnosis for women with gonorrhoea 
and a 3-fold higher odds for women with a chlamydia infection.  In view of this high individual 
risk of PID associated with gonorrhoea, an increased risk of PID hospitalisation after  
gonorrhoea,40 41 and, recent increases in gonorrhoea rates for Australian women,34 a 
continued focus on gonorrhoea and chlamydia case detection and PID diagnosis for women 
at STI risk or presenting with pelvic pain is essential.  Case detection must be complemented 
by other aspects of management including timely partner management and retesting after 
treatment toward reducing reinfections and PID. 
This manuscript was selected as editor’s choice on the journal website. 
54 
 
Chapter 4:  Characteristics of pathogen negative PID 
PUBLISHED: Goller JL, De Livera AM, Fairley CK, Guy RJ, Bradshaw CS, Chen MY, Hocking JS. 
Characteristics of pelvic inflammatory disease where no sexually transmitted infection is 
identified: a cross-sectional analysis of routinely collected sexual health clinic data. Sexually 
Transmitted Infections, 2017 93(1):68-70.  doi:10.1136/sextrans-2016-052553 
Reproduced with permission from BMJ Publishing Group Ltd (Copyright notice 2017). 
4.1 Introduction 
An additional finding in Chapter 3, was that 61% of PID cases did not have an infection 
identified.  The clinical features of PID are known to vary with different pathogens; recent 
onset abdominal pain has been reported more often by women with gonorrhoeal PID than 
chlamydial PID85 and systemic inflammatory markers are more common in women with 
gonorrhoeal PID than chlamydial or M. genitalium PID.140  However, the characteristics of PID 
without an identified pathogen have been infrequently reported.  
Chapter 4 presents findings from a further analysis of routinely collected sexual health clinic 
data that was published in Sexually Transmitted Infections.269  The study population 
comprised 330 women with clinically diagnosed PID and all were tested for chlamydia, 
gonorrhoea, M. genitalium and bacterial vaginosis.  The demographic, behavioural and clinical 
characteristics of pathogen-negative PID (a PID diagnosis where chlamydia, gonorrhoea, M. 
genitalium and bacterial vaginosis tests conducted during the visit were all negative) were 
compared with pathogen-positive PID (a PID diagnosis and positive test for one or more of 
chlamydia, gonorrhoea, M. genitalium or bacterial vaginosis).  The methods in this chapter 
are detailed in the following publication. Due to the analysis being based on available data 
from the electronic patient record the clinical variables consisted of laboratory test results 
and assessment of vaginal inflammation measured by poly-morphonuclear leucocyte count 
from high vaginal swab specimens.  Multivariable logistic regression was conducted to assess 
whether pathogen-negative PID differed to pathogen-positive PID, with the analysis clustered 












4.2 Chapter summary 
The publication in Chapter 4 identified that of 330 women with clinically diagnosed PID, that 
62% had no pathogen identified.  This finding is consistent with other studies finding no 
pathogen in a large proportion of PID cases.18 19 140 Women in this study with clinical evidence 
of PID but no pathogen were more likely to be aged >30 years (AOR 1.7, 95%CI 1.0, 3.0) and 
less likely to have evidence of vaginal inflammation (AOR 0.5, 95%CI 0.3, 0.9) or to report 
recent unprotected sex (AOR 0.6, 95%CI 0.4, 1.0) than women with chlamydia, gonorrhoea, 
M. genitalium and/or bacterial vaginosis associated PID.  
The findings illustrate uncertainties about PID diagnosis and aetiology and the need for 
biomarkers of upper genital tract inflammation that can improve certainty of a PID diagnosis.  
In the absence of well validated, objective and non-invasive diagnostic methods for PID 
diagnosis, the decision to initiate treatment for mild to moderate PID is reliant on sensitive 
minimum clinical criteria that aim to lessen the number of PID cases that are missed.13 The 
publication highlights the need for clinicians to weigh up the potential consequences of 
under-diagnosis of PID that could result in future adverse reproductive impacts270 versus 
over-diagnosis of PID that exposes women to unneeded antibiotic treatment. However, 
reported side effects requiring discontinuation of PID treatment are infrequent.213 Although 
the study found that pathogen negative PID cases were at lower sexual risk than pathogen 
positive PID, the overall study population was high risk when compared to a national 
sample.271  Sexual risk is an important factor for clinicians when considering differential 
diagnoses for a woman with new onset low abdominal pain.   
The main characteristic differentiating women with pathogen-negative and pathogen-
positive-PID was reduced evidence of vaginal inflammation.  Several studies have assessed 
indicators of lower genital tract inflammation for their use in supporting a PID diagnosis, but 
providing mixed evidences.  The presence of mucopus or white blood cells in vaginal discharge 
from a sample of women enrolled in the PEACH study was shown to be a sensitive test for 
upper genital tract infection (as confirmed by endometrial biopsy).203 In contrast, a review of 
13 studies (including the PEACH study) reported that for women with clinical evidence of PID 
that the presence or absence of vaginal or cervical discharge was not helpful in making or 
excluding a PID diagnosis.272  
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Chapter 4 also provides updated evidence about the frequency of pathogens in Australian PID 
cases that can inform PID management guidelines.  Among the 330 PID cases in this 
publication, bacterial vaginosis was the most frequent infection, diagnosed in 21.5% (n=71) 
cases, followed by chlamydia (18.8%, n=62), M. genitalium (4.5%, n=15) and gonorrhoea 
(2.4%, n=8).  In addition to the published results, 25 of the PID cases had more than one 
infection diagnosed, all but two were coinfected with bacterial vaginosis. The breakdown of 
these coinfections included chlamydia and bacterial vaginosis (n=13), M. genitalium and 
bacterial vaginosis (n=4), chlamydia, gonorrhoea and bacterial vaginosis (n=4), chlamydia and 
M. genitalium (n=2), and one each of gonorrhoea and bacterial vaginosis, and, chlamydia, M. 
genitalium and bacterial vaginosis.   
The microbial causes of PID are difficult to determine.  Respiratory, enteric or novel bacteria 
and bacterial vaginosis associated pathogens have been identified in the upper genital tract 
of women with non-gonococcal or non-chlamydial PID, although some of these pathogens 
have also been present in women without PID.2 96-99 PID is associated with bacterial vaginosis, 
but it is unclear if bacterial vaginosis causes PID.  Several studies have assessed specific 
bacterial vaginosis pathogens, reporting that women with high levels of Gram negative 
anaerobes in the lower genital tract were at higher risk of PID.97 166 177 Women with bacterial 
vaginosis are also at higher risk of incident chlamydia or gonorrhoea infection180 that could in 
turn increase risk of ascending infection. However, for these cross-sectional data, the 
temporal relationship between bacterial vaginosis and acquisition of other STIs or developing 
PID is not known.   Based on available evidence, pathogen-negative PID in this publication 
could represent a false positive PID diagnosis, PID of another microbial aetiology or associated 





Chapter 5:  Time trends in PID diagnosis in an Australian sexual 
health clinic 
SUBMITTED for publication to Sexual health on 10th October 2018 (under review): Goller JL, 
Fairley CK, De Livera AM, Chen MY, Bradshaw CS, Chow EPF, Guy RJ, Hocking JS. Trends in 
diagnosis of pelvic inflammatory disease in an Australian sexual health clinic, 2002 to 2016: 
before and after clinical audit feedback and service improvements. 
5.1 Introduction 
Chapter 5 addresses objective two of this thesis and investigates time trends in PID diagnosis 
in an Australian sexual health clinic.  It is well known that clinical diagnosis of PID is imprecise 
and that PID practices can vary between clinicians and health care settings.44 45 Guidelines 
recommend that clinicians have a high degree of suspicion and low threshold for initiating PID 
treatment if suspected in sexually active women presenting with abdominal pain and where 
other diagnoses are excluded.13   
Previously, a clinical audit at a large Australian sexual health clinic reported variability in PID 
diagnosis rates between doctors and concluded that some PID cases were likely to have been 
missed.44 After the audit, doctors were given feedback and some actions were undertaken 
that sought to improve consistency of PID diagnosis between doctors, and to increase PID 
diagnosis rates.  To date, there has been no assessment whether PID diagnosis trends have 
altered following this audit.  
Chapter 5 presents findings from an analysis of Australian sexual health clinic data that 
investigated PID diagnosis characteristics and trends over time before and after audit 
feedback.  A manuscript of the findings has been prepared and submitted to the journal 
Sexual Health and is currently under review.  The methods used in this chapter are detailed 
in the following manuscript. In brief, yearly rates of first PID diagnosis for women aged 16-49 
years attending the sexual health clinic between 2002 and 2016 were 
calculated.  Multivariable generalized linear mixed models; adjusting for patient risk and an 
STI (chlamydia, gonorrhoea, M. genitalium) and/or bacterial vaginosis diagnosis; and, 
stratified by the period before and after feedback; were used to assess if PID rates changed 
over time, accounting for between-doctor variability.  
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TITLE: Trends in diagnosis of pelvic inflammatory disease in an Australian sexual health clinic, 
2002 to 2016: before and after clinical audit feedback  
Authors: Goller JL, Fairley CK, De Livera AM, Chen MY, Bradshaw CS, Chow EPF, Guy RJ, 
Hocking JS. 
ABSTRACT  
Background: An audit of PID diagnosis rates in an Australian sexual health clinic in 2006 found 
variability between doctors. Doctors were given audit feedback toward increasing PID 
detection and reducing variability. The clinic implemented other improvements to increase 
capacity. This study investigated PID diagnosis trends over time before and after audit 
feedback.   
Methods: Yearly rates of first PID diagnosis for women 16-49 years attending Melbourne 
Sexual Health Centre (2002-2016) were calculated. Multivariable generalized linear mixed 
models; adjusting for patient risk and sexually transmitted infection (STI) (chlamydia, 
gonorrhoea, Mycoplasma genitalium) and/or bacterial vaginosis (BV) diagnosis; and, 
stratified by before (July2002-June2007) and after (July 2007-June2016) feedback; were used 
to assess if PID rates changed over time, accounting for between-doctor variability.  
Results: During the study-period, 144 doctors undertook 84,476 female consultations and 
diagnosed 1755 (2.1%, 95%CI: 2.0-2.2) with PID.  Comparing 2002-03 to 2015-16, the yearly 
PID rate increased from 0.8% (37/4836) to 2.9% (209/7088), and comparing before and after-
feedback, a higher proportion of women reported any symptoms at triage (35.1% to 47.2%or 
had STI/ BV diagnosed (10.1% to 14.9%). After feedback, univariable analysis showed PID 
rates increased by 8% yearly (incidence rate ratio, IRR 1.08, 95%CI: 1.06-1.11), but, were 
unchanged (aIRR 1.01, 95%CI: 0.98-1.03) after adjustment for patient characteristics. Factors 
associated with PID were self-report of any symptoms at triage, age (16-29 years), and an 
STI/BV diagnosis. Lower variability in doctor-specific rates was observed after-feedback.  
Conclusion: Increasing rates of PID diagnosis were driven by an increasing risk profile of 




Pelvic inflammatory disease (PID) is an inflammatory disorder of the female upper genital 
tract that occurs following infection ascent from the lower genital tract.(1, 2) The sexually 
transmitted infections (STIs) Chlamydia trachomatis (chlamydia), Neisseria gonorrhoea 
(gonorrhoea)(2-4) and Mycoplasma genitalium (MG) are known PID causes(5) and there is a 
strong association with bacterial vaginosis (BV).(6)  
Pelvic pain is a key characteristic of PID. Other features can include abnormal vaginal 
discharge, bleeding or dyspareunia although many women experience no signs or symptoms 
as infection ascends to the upper genital tract, causing subclinical PID that is diagnosed via 
laparoscopy.(1)  PID can have serious reproductive sequelae including infertility, chronic 
pelvic pain and ectopic pregnancy.(7, 8) To minimise the risk of such complications, it is 
important that PID is diagnosed and treated promptly.(9) However, PID is notoriously difficult 
to diagnose.  Most diagnoses are clinically made and there is no objective non-invasive 
diagnostic test or physical feature both sensitive and specific to PID diagnosis.(1) The 
presence of one or more of uterine, cervical motion or adnexal tenderness in sexually active 
women with recent onset pelvic pain are widely used as minimum criteria for initiating PID 
treatment.(10, 11) 
Guidelines recommend that clinicians have a low threshold for PID diagnosis.(10, 11) 
However, the condition’s non-specific nature creates potential for diagnostic inconsistencies.  
In the United Kingdom, a survey of general practitioners found a fifth of respondents reported 
PID diagnostic practices that were consistent with a ‘gold standard’(12) and in Australia, a 
clinical audit in remote primary health services found PID was diagnosed in only 16% of 
presentations meeting PID diagnostic criteria.(13) (14) 
A clinical audit, in an Australian sexual health clinic previously identified variability in rates of 
clinically diagnosed PID between doctors and concluded some PID cases were likely to have 
been missed.(15)  Following the audit(15) the clinic reviewed its PID diagnosis and 
management procedures and undertook several actions seeking to improve consistency of 
PID diagnosis between doctors, and to increase PID diagnosis rates.  These actions included 
benchmarking in which doctors received their own PID diagnosis rate compared to the 
63 
 
average, a clinical meeting to discuss the audit results and PID diagnostic criteria, and, 
addition of a PID checklist used during triage of chlamydia or MG positive women attending 
for treatment.  Gonorrhoea diagnosis among women was infrequent in the clinic at this 
time.(16) There was no follow up audit at the clinic. The aim of this study was to investigate 
PID diagnosis trends over time before and after audit feedback, adjusting for patient 
characteristics.   
Methodology 
We conducted an analysis of PID diagnosis trends over time using retrospective routinely 
collected data for female patients aged 16-49 years attending an Australian sexual health 
clinic between July 2002 and June 2016.   
Melbourne Sexual Health Centre (MSHC) is the major public sexual health clinic in the state 
of Victoria, Australia and provides a free walk-in triage based service.(17) Women reporting 
high risk behaviour, with symptoms suggesting an STI, or pelvic pain are triaged into the clinic.  
Patients are seen in the order they are triaged.  Symptomatic patients are seen by a doctor 
and less complicated patients by a nurse or doctor, depending on availability.  Doctors include 
a mix of sexual health physicians and trainees, infectious disease physicians and doctors on 
placements toward general practitioner or infectious disease training. 
Data for each patient attendance are recorded in the electronic medical record (EMR) that 
collects demographics, self-reported symptoms at triage (e.g. pain, vaginal discharge) and 
self-reported risk information for first or repeat visits >3 months apart, and, clinician entered 
data including investigations and diagnoses (selected from a diagnosis code list). Chlamydia 
testing is routinely offered to all new female patients. Women with suspected PID are also 
tested for gonorrhoea, BV, and, since 2011 for MG.  Female sex-workers attend regularly for 
health checks that include chlamydia and gonorrhoea testing.  
PID diagnosis at MSHC is clinical and guided by local guidelines that are updated routinely to 
reflect national and international guidelines.  The minimum criteria being the presence of 
cervical motion tenderness or uterine tenderness or adnexal tenderness in young sexually 
active women or other women at STI risk who are experiencing pelvic or lower abdominal 
pain and no other cause is identified.(10)  These PID diagnostic criteria did not change 
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markedly throughout the study period. However, before 2002, Centers for Disease Control 
guidelines recommended PID treatment be commenced where all three features of 
abdominal, cervical motion and adnexal tenderness were present.(18)   
Previously, MSHC undertook a clinical audit for the period July 2002 to June 2006 that showed 
variable PID diagnosis rates between doctors.(15) The audit results were finalised in the first 
half of 2007. In late 2007, doctors were provided with written feedback about the audit 
findings, their own PID diagnosis rate, and, how it compared with the overall rate.  The audit 
results were discussed at a clinical meeting attended by doctors and nurses that highlighted 
the importance of diagnostic sensitivity rather than specificity, and, the clinic reviewed its PID 
diagnosis and management guidelines.  There was no formal change to the clinic’s PID 
guidelines.  In addition, a PID checklist that assessed for presence of pelvic pain, abnormal 
discharge, deep dyspareunia or abnormal uterine bleeding was added to a clinical assessment 
proforma used during nurse triage of chlamydia or MG positive patients attending for 
antibiotic treatment.  Women with any of these symptoms were subsequently assessed by a 
doctor.   
For this study, women aged 16-49 years who attended MSHC between July 2002 and June 
2016 and were assessed by a doctor were eligible.  Demographic, risk [number of male sexual 
partners (MSP) and condom-use in the past 3 months, STI contact, sex work], and clinical data 
(test results, diagnosis codes, details of attending doctor) were extracted for eligible women 
from the EMR. To maximise the number of eligible consultations, risk behaviour information 
for repeat visits <3 months apart by eligible women was applied from earlier visits where 
available. PID was the primary outcome and based on a PID diagnosis code, only the first PID 
diagnosis for any woman was included. Binary variables were created for demographics, risk 
[unprotected (condomless) sex with non-regular MSP in the past 3 months, STI contact], and, 
diagnosis of a lower genital infection (chlamydia, gonorrhoea, MG and/or BV) during the 
current visit.  Diagnosis of these infections was based on laboratory results; chlamydia and 
gonorrhoea by nucleic-acid-amplification from urine, vaginal or endocervical swabs, with 
microscopy and culture for women testing positive gonorrhoea; MG by polymerase-chain-
reaction on urine, vaginal or endocervical swabs; and BV by microscopy, predominantly a 
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Nugent score of 7-10, or 4-6 with clue-cells. A categorical time variable for each 12-months 
from July to the following June (e.g. July 2007 to June 2008) was created.   
The Alfred Health Human Research Ethics Committee (EC00315) provided study approval. 
Statistical analysis  
Data were analysed using STATA statistical software, v14.0.  Yearly PID diagnosis rates per 100 
female consultations by doctor were calculated.  Age, self-report of any symptoms at triage, 
diagnosis of a lower genital tract infection, recent unprotected sex, self-reported STI contact, 
and sex work were identified a priori as confounders. We used a generalized linear mixed 
effects model, stratified by the time-period before (July 2002 to June 2007) and after (July 
2007 to June 2016) audit feedback to assess if yearly PID diagnosis rates changed linearly over 
time, with a random-intercept term at doctor level to account for between-doctor variability, 
and, adjusted for potential confounders in multivariable models. We report incidence rate 
ratios (IRR) with 95% confidence intervals (95% CI).   
Results 
Over the 14-year study period, there were 144 doctors who worked at MSHC and undertook 
84,476 consultations for women aged 16-49 years, among whom 1755 (2.1%; 95%CI: 2.0-2.2) 
were diagnosed with PID.  For these doctors, the yearly doctor specific PID diagnosis rate 
ranged from 0% to 13% (median: 1.0, IQR: 0-2.8). The yearly number of PID cases and female 
consultations and the PID diagnosis rate increased over time; from 0.8% (37/4836) in 2002-
03 to 1.7% (100/5828) in 2007-08, up to 2.3% (157/6843) in 2010-11 and then 2.9% 
(209/7088) in 2015-16 (Figure 1).  The characteristics of women assessed by these doctors 
changed over time (Table 1, Figure 2). Comparing the before and after-feedback periods the 
proportion of consultations for which a woman reported any symptoms at triage increased 
from 35.1% to 47.2% or recent unprotected sex from 16.0% to 25.7%. The proportion of 
female consultations for which an STI or BV was diagnosed was higher in the after-feedback 
period (14.9%) than before (10.1%) (table 1). After-feedback chlamydia was diagnosed in 4.3 
, gonorrhoea in 0.5% and BV in 14.9%of consultations. .  For all chlamydia or gonorrhoea 
diagnoses, 57.1% in the after-feedback period, were in women reporting any symptoms at 
triage compared to 38.5% before-feedback.   
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Univariable analyses indicated that, PID diagnosis rates increased by 19% yearly during the 
before-feedback period (IRR 1.19, 95%CI: 1.10-1.29) and 8% yearly (IRR 1.08, 95%CI: 1.06-
1.11) in the after-feedback period (Table 2). Multivariable analyses indicated that PID 
diagnosis rates during the after-feedback period were unchanged (aIRR 1.01, 95%CI: 0.98-
1.03) when adjusted for patient characteristics, while the rates remained the same during the 
before-feedback period (aIRR 1.19, 95% CI 1.10-1.28). The estimated variances of the random 
intercept terms between the doctors were 0.62, (95%CI: 0.32-1.22) during the before-
feedback period and 0.26, (95%CI: 0.16-0.42) during the after-feedback period. Self-report of 
any symptoms at triage had the strongest association with a PID diagnosis, and, other factors 
included younger age (16-29 years), diagnosis of a lower genital tract infection, and, attending 
the clinic as an STI contact.  Self-report of recent unprotected sex was associated with a PID 
diagnosis in the after-feedback period.   
 
Figure 1: Number of PID cases and PID diagnosis rates, 2002-2016 
 
 

































































2002-03 2004-05 2006-07 2008-09 2010-11 2012-13 2014-15
...
PID rate 95% CI PID cases
Note: PID rate and PID cases are plotted on different scales
NETS: Nurse express testing service implemented
Sex Work Act update: determined three months as the time period for screening commercial sex workers
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Table 1: Characteristics of female patients consulted with by doctors before and after audit 
feedback, 2002-2016 
 Before feedbacka After feedbackb  
 n % n % 




PID diagnosed 377 1.4 1378 2.4 
Aged 16-29 years 16219 61.9 35708 61.3 
Self-reported symptoms at triage 9199 35.1 27478 47.2 
Self-reported STI contact 354 1.4 1472 2.5 
Current sex worker 4674 17.8 14682 25.2 
Unprotected sex with non-regular MSPd, last 3 months 4199 16.0 14954 25.7 
Lower genital tract infection diagnosedc 2641 10.1 8680 14.9 
Chlamydia diagnosed 760 2.9 2496 4.3 
Gonorrhoea diagnosed 36 0.1 274 0.5 
MG diagnosed 17 0.1 329 0.6 
BV diagnosed 1927 7.4 6199 10.6 
a. July 2002 to June 2007; b. July 2007 to June 2016; c. One or more of chlamydia, gonorrhoea, MG or BV diagnosed during 
this attendance; d. Male sexual partner        
 
Figure 2: Characteristics of female patients, 2002-2016 
 
  


































2002-03 2004-05 2006-07 2008-09 2010-11 2012-13 2014-15
Symptoms Unprotected sex
STI or BV diagnosed STI contact
STI or BV: chlamdia, gonorrhoea, M. genitalium, bacterial vaginosis
NETS: Nurse express testing service implemented
Sex Work Act update: determined three months as the time period for screening commercial sex workers
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Table 2: Factors associated with PID diagnosis rates before and after audit feedback, 2002-
2016 
 Before feedbacka After feedbackb  
 Univariable Multivariable Univariable Multivariable 
 IRR  (95%CI) aIRR  (95%CI) IRR  (95%CI) aIRR  (95%CI) 
Study time, year 1.19  (1.10-1.29) 1.19  (1.10-1.28) 1.08  (1.06-1.11) 1.01  (0.98-1.03) 
Self-reported symptoms         
No  1.0  1.0  1.0  1.0  
Yes 4.76  (3.79-5.97) 4.58  (3.57-5.86) 6.24  (5.37-7.25) 5.33  (4.55-6.24) 
Patient age         
16-29 years 1.48 (1.18-1.84) 1.35  (1.08-1.69) 1.91  (1.69-2.16) 1.49  (1.31-1.69) 
30-49 years 1.0  1.0  1.0  1.0  
Lower genital tract 
infectionc 
        
No 1.0  1.0  1.0  1.0  
Yes 3.19  (2.55-4.00) 2.10  (1.67-2.65) 2.69  (2.41-3.01) 1.71  (1.52-1.92) 
Unprotected sex with 
non-regular MSPd, last 3 
months 
        
No 1.0  1.0  1.0  1.0  
Yes 1.56  (1.23-1.98) 1.22  (0.96-1.56) 1.89  (1.70-2.11) 1.34  (1.20-1.50) 
Current sex worker         
No  1.0  1.0  1.0  1.0  
Yes 0.56  (0.41-0.77) 1.03  (0.73-1.43) 0.50  (0.43-0.58) 1.04  (0.88-1.22) 
Self-reported STI contact         
No 1.0  1.0  1.0  1.0  
Yes 2.21  (1.24-3.93) 4.01  (2.18-7.38) 2.13  (1.68-2.69) 2.01  (1.58-2.55) 
a. July 2002 to June 2007; b. July 2007 to June 2016; c. One or more of chlamydia, gonorrhoea, MG 
or BV diagnosed during this attendance; d. Male sexual partner        
Discussion 
This study assessed PID diagnosis trends over time before and after audit feedback in a sexual 
health clinic. Although we found that PID diagnosis rates increased after audit feedback, the 
increase was explained by a marked increase in the risk profile of female patients assessed by 
doctors in the clinic. This after-feedback period was also characterised by substantial 
increases in the yearly number of both female consultations and PID cases diagnosed. We 
also found that there appeared to be less deviation in doctor-specific rates from overall PID 
rates in the period following feedback than before.   
Our study had several strengths.  First, our multivariable analysis accounted for clustering by 
clinician to account for variable diagnostic practices between doctors over time.  Second, 
inclusion of patient risk factors allowed our multivariable analysis to account for a changing 
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risk profile of women that impacted on PID diagnosis over the 14-year study period. Our 
studies main limitation was that we could not verify the accuracy of PID diagnoses or 
determine the severity of PID cases diagnosed. Standard practice at MSHC is to review PID 
cases within three days to assess a clinical response to antibiotic treatment.  Failure to 
improve suggests another diagnosis or a need for alternative antibiotics.(19) Although women 
reporting any symptoms at triage were over five times more likely to be diagnosed with PID, 
these routinely collected data did not have detail of the severity of signs and symptoms or 
clinical assessment that supported the clinician to diagnose PID or assess treatment response. 
However, the characteristics associated with a PID diagnosis were largely consistent with PID 
guidelines and risk factors.(10, 20) 
PID diagnosis is imprecise and diagnostic sensitivity can vary between doctors.(14, 15) In this 
sexual health clinic, an audit in 2006 identified differences in PID diagnosis rates between 
doctors and led to actions around a decade ago toward improving consistency of PID 
diagnostic criteria between doctors.  Until this study, there has been no assessment of what 
happened after the audit response.  The discussions following the PID audit centred largely 
on the merit of being more sensitive versus more specific to a PID diagnosis, with no formal 
change to the clinic’s diagnostic criteria. Doctors were encouraged to reflect on their own 
diagnostic criteria, on the basis that those who diagnosed PID at a low rate might increase 
their diagnostic sensitivity.  Anecdotally some doctors considered that the benchmarking and 
discussions helped them to appraise their diagnostic criteria. The PID checklist may have 
helped identify symptoms suggestive of PID in women returning for STI treatment and for 
diagnosis of additional PID cases. While, our finding of less PID diagnostic variability after 
audit feedback suggests some change in clinical practice, it is uncertain whether this was 
because of the audit. There is a risk that an emphasis on diagnostic sensitivity could come at 
the expense of specificity. Clinicians who are highly sensitive to PID might diagnose PID in 
healthy women (over-diagnosis), or, in women with another condition (misdiagnosis) such as 
appendicitis.  A false-positive diagnosis could delay care for another condition, expose women 
and their sexual partners to STI-related stigma and to unnecessary antibiotic treatment with 
implications for antimicrobial resistance. The risk of over-diagnosis could be higher for less-
experienced doctors. A cross-sectional study in the UK showed PID diagnostic acumen was 
greater with more clinical experience.(15)  
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Such diagnostic challenges are not new and have prompted assessment of the clinical criteria 
that best correlate with upper genital tract infection.  A secondary analysis of data for over 
600 Swedish obstetrics and gynaecology patients in the 1960s reported that lower abdominal 
pain had a pretest probability of 79% for laparoscopically diagnosed PID but showed no 
meaningful difference between pre and post-test probabilities for most signs and 
symptoms.(21) These uncertainties about PID diagnosis in the Swedish(21) and more recent 
data(22) highlight the need for a simple test that can accurately diagnose PID.  While a range 
of biomarkers for upper genital tract inflammation are being investigated,(23, 24) objective 
tests for clinical use are some way off.   
In this study, changes in the patient risk profile appear to have had the greatest impact on PID 
diagnosis rates.  Univariable analysis showed that PID rates increased by 8% yearly after audit 
feedback, but this increase was not apparent after adjusting for patient characteristics in 
multivariable analysis.  The decade since audit feedback involved other changes that may 
have impacted on PID diagnosis, even if not specifically PID focussed. MSHC is the only full-
time and free sexual health service in the Australian state of Victoria, the population of which 
now exceeds 6 million.(25) As the Victorian population and demand for services grows, the 
clinic has implemented processes (largely within existing resources) toward improving clinical 
efficiency while maintaining optimal care. In 2010, MSHC implemented a nurse express 
testing service,(26) in which asymptomatic heterosexuals at STI risk complete a sexual history, 
collect their own samples,  receive phone results, and reattend the clinic for treatment if 
positive.  This nurse led service has streamlined care for many asymptomatic heterosexual 
patients and increased capacity for greater numbers of patients including high risk 
symptomatic patients to attend the clinic. Furthermore, an update to the Victorian Sex Work 
Act (2012) determined the time period for screening of people in the sex industry as three 
monthly (previously monthly), thereby reducing sex worker consultations,(27) and, increasing 
capacity for other patients and STI diagnosis.(28) Female commercial sex workers have had a 
low STI prevalence in the state of Victoria.(29)  In this context of improved clinical efficiencies, 
doctors in this study undertook an increasing number of female consultations, including for 




Population-based sexual behaviour data show increasing numbers of lifetime sex partners for 
young Australians, potentially increasing their STI risk.(30) This combined with surveillance 
data that show increasing gonorrhoea rates for women that cannot be explained by increased 
testing appears to reflect increasing transmission in these populations(31)  Chlamydia 
diagnoses have also increased and although influenced by testing, annual chlamydia testing 
levels in Australia are low, testing only 15% of 15-29 year-olds in 2016.(31) These increases in 
sexual risk practices and STIs  could translate into increasing PID diagnoses in this and other 
clinical settings.  
So, what are the implications for PID diagnosis in other clinical settings. In the absence of new 
diagnostics, there is an ongoing need for tools, training and processes that can support 
clinicians to consider both sensitivity and specificity within PID diagnostic criteria. General 
practice is an important provider of care for mild to moderate PID in Australia(11, 32) however 
sexual health care is not core business.  Recent Australian data show that less than half of 
general practitioners (GPs) asked about female pelvic symptoms with STI treatment.(33) The 
PID checklist used in this clinic is brief and could be a resource to remind GPs of the possibility 
of PID when treating women with an STI.  Other resources developed for Australian general 
practice include an algorithm for assessing abdominal pain in reproductive age women and a 
guide to bimanual examination.(34) The challenge is to systematise such resources into 
routine care. Hyperlinks in positive test results have been used to increase GP access to 
partner notification resources(35) and could help integrate PID resources into care. This 
would ideally be complemented by education and training and establishment of indicators to 
monitor PID diagnosis over time.  In this clinic, service improvements that increased capacity 
for care of more complex patients by doctors and more asymptomatic patients by nurses(26) 
appeared to have the greatest impact on PID diagnosis.  Other strategies involving doctors 
and nurses have had some success in improving PID diagnosis.  A multifaceted intervention in 
a North American emergency department targeted medical and nursing staff  (education, 
posters of PID treatment guidelines) and patients (written discharge handout) and showed 
improvements in PID diagnosis, treatment, and, sexual history taking for young women 
presenting with lower abdominal pain.(36)  The potential for models of care that incorporate 




Availability of best practice care is essential for women at risk of PID and STIs. Clinical audit 
offers a mechanism for improvements in clinical practice and reorientation of services can 
increase capacity.  In this Australian sexual health clinic, it was uncertain whether PID specific 
actions after a clinical audit led to changes in PID diagnostic sensitivity but service 
improvements appeared to have had a greater impact on PID trends, providing additional 
capacity for high-risk patients and an increase in the overall number of PID cases diagnosed 
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5.3 Chapter summary  
The study in Chapter 5 investigated long-term PID diagnosis characteristics and trends at a 
large sexual health clinic, before and after clinical audit feedback.   The study found that 
between 2002 and 2016, 144 doctors undertook 84,476 female consultations and diagnosed 
2.1% with PID, with the yearly PID diagnosis rate increasing from 0.8% (37/4836) to 2.9% 
(209/7088) and an increasing proportion of women reported any symptoms (35.7% to 56.6%) 
or diagnosed with an STI or bacterial vaginosis (9.4% to 21.4%).  After audit feedback in 2007, 
univariable analysis showed PID rates increased by 8% yearly (incidence rate ratio, IRR 1.08, 
95%C: 1.06, 1.11), but, were unchanged (aIRR 1.01, 95%CI 0.98, 1.03) after adjustment for 
patient characteristics in multivariable analysis. Since audit feedback, the clinic has reoriented 
services to increase patient capacity including for high risk patients that appear to have had 
a greater impact on PID diagnosis rates than audit feedback. For example, the clinic 
introduced a nurse led service in 2010 that streamlined care for asymptomatic heterosexual 
patients, thereby increasing capacity for more high risk symptomatic patients to attend the 
clinic.273 
This was the first analysis of PID time trends in an Australian sexual health clinic. This study 
highlights the importance of both clinical audit as a mechanism to identify areas for 
improvements in clinical practice and reorientation of services to improve clinical efficiencies. 
This Chapter demonstrates the importance of adjustment for patient characteristics in 






Chapter 6:  Time trends in PID diagnosis in Australian hospitals  
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6.1 Introduction 
This Chapter addresses the third objective of this thesis, to estimate time trends in PID 
diagnosis in Australian hospitals.  Previous analyses of Australian data have shown declining 
PID rates in hospital admissions during the 1990s and 2000s.14 24 238 The most recent national 
PID rates extend to 2007. Ectopic pregnancy and infertility that occur due to fallopian tube 
scarring are serious sequelae of PID.246 247.  Declining ectopic pregnancy rates in Australian 
hospitals have been reported to as recently as 2007.14 239   
Since these reported declines, a cluster randomised controlled trial (ACCEPt)256 264 of a 
chlamydia testing intervention in Australian primary care clinics was conducted.  ACCEPt 
investigated the effectiveness of annual chlamydia testing for 16-29-year-old women and 
men in primary care on chlamydia prevalence in the population.  A secondary aim was to 
investigate the effect of the intervention on PID incidence.  Toward this objective, hospital 
admission and emergency department data involving a PID diagnosis were collected.  In 
addition, admission and emergency department data were collected for ectopic pregnancy, 
and, orchitis or epididymitis for men.   
This Chapter presents findings from an ecological study published in Sexually Transmitted 
Infections.274 Although PID is the outcome of focus in this thesis, ectopic pregnancy rates were 
investigated in this chapter as another measure of female reproductive tract morbidity.  The 
publication presents an analysis of yearly PID and ectopic pregnancy rates in the three most 
populous states of Australia (NSW, Victoria and Queensland) for women aged 15-44 years for 
the period 2009 to 2014.  Rates were calculated using routinely collected hospital admission 
and emergency department attendance data as the numerator, and, population and live birth 
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denominators.  This is the first analysis to include Australian emergency department data 
toward a measure of these outcomes. The methods used in this chapter are detailed in the 
following publication.  In brief, univariable and multivariable Poisson regression models were 
used to examine variation in PID and ectopic pregnancy rates by year, age-group and 
remoteness and socio-economic disadvantage of residential area.  A stratified analysis of PID 
admission rates was conducted by PID category, being chlamydia or gonorrhoea related PID, 
acute PID, unspecified PID and chronic PID.  Further detail of the data sources, a breakdown 
of the annual number of cases and coding sensitivity analyses and sensitivity analysis findings 
were published as additional material that was published online only and are provided in 



























6.2 Chapter summary  
This publication identified that rates of PID diagnosis in hospital admissions across three 
states (NSW, Victoria and Queensland) were similar between 2009 and 2014, which is in 
contrast with earlier downward trends observed in Australia and many other countries.24 
Investigation by PID category, showed that between 2009 and 2014 that admission rates 
increased by 73% for chlamydia or gonorrhoeal related PID, by 9% for unspecified PID, and, 
declined by 17% for chronic PID.  Although overall PID admission rates varied little by age, 
chlamydial/gonorrhoeal PID rates were 11.7 times higher among women aged 15-24 than for 
women aged 35-44 years.  Inclusion of emergency department data provided new 
information about PID diagnosis in Australia. The publication identified that emergency 
departments care for many more PID cases in addition to those managed as inpatients, that 
PID rates in emergency departments increased by 34% between 2009 and 2014, and, were 
substantially higher for younger than older women.  The ectopic pregnancy analysis showed 
higher rates among live births in 2014 compared with 2009 in admissions and emergency 
departments. Although most ectopic pregnancy cases were admitted to hospital, an 
increasing proportion were managed without admission.  Increasing disadvantage and 
remoteness of residential area tended to be associated with higher PID and ectopic pregnancy 
rates. 
Interpretation of these findings is not straightforward.  For PID, admissions data tell us largely 
about severe PID. However most PID cases are mild to moderate in severity and can be 
managed in primary care.  Hence primary care data are need for a more comprehensive 
picture of PID.  Increasing PID rates in the emergency department could suggest an increase 
in PID incidence but could also reflect changing healthcare usage. Over two thirds of women 
diagnosed with PID in the emergency department were managed without admission.  It is 
possible that some of these women may have been suitable for management in primary care 
but that factors restricting access to primary care influenced them to attend the emergency 
department instead.275 276 The higher PID rates observed among younger women, in particular 
STI associated PID admissions, and, PID in the emergency department, are consistent with 
higher chlamydia and gonorrhoea notification rates in this age group.34 Rates of chronic PID 
were higher for older women which is consistent with other studies.14 The decline in chronic 
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PID admission rates could reflect earlier declines in acute PID, that led to a smaller pool of 
women at risk of chronic PID. The challenges in measuring PID and EP rates in this study 
highlight the need for improved data sources and surveillance that include hospital and 
primary care to facilitate comparable measures over time. Considering systems for 
monitoring PID incidence are limited, this Chapter shows how ecological analyses of data from 





Chapter 7:  Discussion and Conclusions 
7.1 Introduction  
As outlined throughout this thesis, PID is a serious reproductive health issue for women that 
occurs when infection ascends from the lower to the upper genital tract.  The STIs, chlamydia 
and gonorrhoea are commonly implicated, however the microbial aetiology of many cases is 
unknown. PID diagnosis is imprecise due to the wide range of possible clinical features and 
absence of an objective and reliable non-invasive diagnostic test.   
In view of the potential long-term consequences of PID, it is essential that we have up to date 
knowledge about the number and distribution of PID cases within populations and the 
associated risk factors, to inform and assess progress against STI policies and programs.  
However, measuring the distribution and determinants for PID is challenging due to the issues 
around diagnosis, the many clinical settings where women with PID might be managed, and 
a scarcity of systems for routinely monitoring PID trends.   
This PhD aimed to improve understanding of the epidemiology of PID diagnosed in Australia, 
particularly with reference to chlamydia infection.  The thesis comprised four major 
components. Two separate quantitative analyses of routinely collected sexual health clinic 
data were undertaken to assess the microbial organisms associated with PID diagnosed in 
Australia. A third analysis of sexual clinic data investigated PID diagnosis characteristics and 
trends before and after clinical audit feedback.  The final component was a quantitative 
analysis of routinely collected hospital data to assess yearly PID and ectopic pregnancy 
diagnosis rates for the period 2009 to 2014. 
7.2 Objective 1 – To investigate the microbial organisms associated with PID 
diagnosed in Australian sexual health clinic attendees 
7.2.1 Population attributable fraction of PID associated with chlamydia and gonorrhoea 
The first component of this thesis sought to estimate the potentially avoidable burden of PID 
if chlamydia or gonorrhoea were eliminated from the population. The findings for the 
population level and individual level risks associated between PID and a current chlamydia or 
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gonorrhoea infection in female sexual health clinic attendees were published in Sexually 
Transmitted Infections268 and are reproduced in full in Chapter 3.   
A key finding in this publication was that for a high chlamydia prevalence clinic population, 
eliminating a current chlamydia infection might at most reduce PID by 14%.  This was lower 
than an estimate of 19.7% derived from modelling of prospective, retrospective and routine 
data (see also Section 2.2.1). These modelled estimates were adjusted for under-
ascertainment of chlamydia in PID cases in the retrospective studies, thereby increasing the 
PAF from 14.5%.109  For a subset of women also tested for gonorrhoea the PAF of PID for 
gonorrhoea was 1%.  A further sub-analysis for asymptomatic women showed that 28% of 
PID was associated with chlamydia but only 0.6% of asymptomatic women were diagnosed 
with PID. 
These PAF findings provide valuable information in the context of ongoing debate as to 
whether chlamydia screening is an effective intervention. A systematic review of chlamydia 
screening trials found that PID risk was 32% lower in women who were offered a single 
chlamydia test compared with women not invited to have a test, although this effect was less 
when lower quality studies were omitted.262 However the 32% reduction was similar to that 
observed recently in the ACCEPt study (also see Section 2.7.1, p 58) where a reduction of 40% 
in PID hospitalisations over a 3 year period was observed.256  Even though there are some 
methodological issues with the trials, the consistency of their results does provide evidence 
for the protective impact of screening on PID.  However, a cost analysis of one of the trials 
included in the systematic review, the POPI trial, estimated that the costs of chlamydia 
screening for women aged 16-24 years and living in London during 2009 were around £4 
million to prevent around 400 cases of PID that incurred £64,000 in total of healthcare costs, 
leading to questions about the cost-effectiveness of screening.263 While there is likely to be 
an individual benefit for those screened, there is unlikely to be sufficient population benefit 
to make it cost-effective.256 For gonorrhoea, the population level findings suggest that 
gonorrhoea elimination in a sexual health clinic population would prevent a much smaller 
proportion of PID than chlamydia elimination, most likely reflecting that gonorrhoea is less 
common among Australian women compared with chlamydia infection.35 Although in 
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consideration that gonorrhoeal PID can be more clinically severe than chlamydial PID, many 
gonorrhoeal PID cases may be represented in hospital rather than sexual health clinic data.   
If Australia were to implement an organised chlamydia screening programme, the main 
setting would be general practice, where over 80% of young 16 to 29-year-old men and 
women attend at least once each year for their primary healthcare,232 and, over 80% of 
Australia’s chlamydia testing and diagnosis takes place.  Given women attending Australian 
general practice are be more likely to be asymptomatic277 than women attending a sexual 
health clinic, the PAF of PID in asymptomatic women provides an indication of how much PID 
might be avoided by chlamydia screening in general practice.  As noted above, the PID 
prevalence for asymptomatic women was 0.6% (equating to 6 cases per 1000 patients) and 
with a PAF of 28%, chlamydia elimination might only avoid 1.7 PID cases per 1000 patients.  If 
considered in the context of the UK cost analysis263 and the ACCEPt study256 it is likely to 
involve considerable costs to prevent these PID cases.  In view of these population level 
findings, concerns about cost effectiveness of chlamydia screening (Section 2.7.1), and high 
rates of reinfection,265 the emphasis of many discussions  about chlamydia and STI control is 
shifting to a focus on primary prevention and strengthened case management. Optimising 
partner  management to prevent reinfection and retesting to detect and treat repeat 
infections earlier are central to this debate.23 115 248 
Although the population findings suggest that widespread screening may not be cost 
effective, the individual level findings showed a 4.4-fold and 3-fold higher odds of a PID 
diagnosis for women testing positive for gonorrhoea or chlamydia respectively than for 
woman testing negative.  These individual level findings are consistent with other Australian 
data showing a higher risk of PID hospitalisation after a recent gonorrhoea or chlamydia 
diagnosis compared with no infection (Section 2.5.2).40 41  In view of continuing high rates of 
chlamydia diagnosis and recent increases in gonorrhoea diagnosis rates for Australian 
women,34 a continued focus on gonorrhoea and chlamydia case detection and PID diagnosis 
for women at STI risk or presenting with pelvic pain is essential.  This information is also 
helpful for clinicians when managing women with a chlamydia or gonorrhoea infection, such 
as informing patients about the risk of PID and what to do should PID symptoms develop and 
in acting as a reminder to assess for presence of symptoms suggestive of PID.   
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7.2.2 Characteristics of pathogen negative PID  
The study in Chapter 3 also found that 61% of PID cases did not have an infection identified, 
leading to a separate analysis of sexual health clinic data investigating the characteristics 
associated with PID without an identified pathogen (pathogen-negative PID). The findings for 
this analysis were published in Sexually Transmitted Infections269 and are reproduced in full 
in Chapter 4.   
This study found that of 330 women with clinically diagnosed PID who were tested for 
chlamydia, gonorrhoea, M. genitalium and bacterial vaginosis, that 62% tested negative for 
the four infections.  This finding is consistent with other studies reporting that no pathogen 
was identified in a large proportion of PID cases.18 19 140 However, the characteristics of PID 
without a pathogen have been infrequently reported.  In this study women with clinical 
evidence of PID but no pathogen were more likely to be aged >30 years and less likely to have 
evidence of vaginal inflammation or to report recent unprotected sex than women with 
chlamydia, gonorrhoea, M. genitalium and/or bacterial vaginosis associated PID.  
The study findings illustrate uncertainties about PID diagnosis and aetiology.  Without well 
validated, objective and non-invasive diagnostic methods for PID diagnosis, the decision to 
initiate treatment for mild to moderate PID is reliant on sensitive minimum clinical criteria 
that aim to lessen the number of PID cases that are missed.13 The study highlights the need 
for clinicians to weigh up the potential consequences of under-diagnosis of PID that could 
result in future adverse reproductive impacts270 versus over-diagnosis of PID that may expose 
women to unnecessary antibiotic treatment. Side effects requiring discontinuation of PID 
treatment are infrequently reported,213 however consideration of the potential for 
antimicrobial resistance, particularly for gonorrhoea and M. genitalium  is important.216 
Although the study found that pathogen negative PID cases were at lower sexual risk than 
pathogen positive PID, the overall study population was high risk when compared to a 
national sample.271  Sexual risk is an important factor for clinicians when considering 
differential diagnoses for a woman with new onset low abdominal pain.   
The main characteristic differentiating women with pathogen-negative and pathogen-
positive-PID was reduced evidence of vaginal inflammation.  CDC guidelines note additional 
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clinical features that if present alongside the minimum clinical criteria can enhance PID 
diagnostic specificity.  These include presence of one or more of elevated temperature, 
cervical friability or mucopurulent discharge, elevated erythrocyte sedimentation rate or C-
reactive protein, abundant vaginal leukocytes, and a lower genital tract chlamydia or 
gonorrhoea infection.13 However, requiring all features to be present comes at the expense 
of diagnostic sensitivity and would reduce the number of cases identified.13 16 201-203 Several 
studies have assessed indicators of lower genital tract inflammation on their own or in 
combination with other criteria for their use in supporting a PID diagnosis.  The presence of 
mucopus or white blood cells in vaginal discharge from a sample of women enrolled in the 
PEACH study was found to have high sensitivity (88.9%) but low specificity (19.4%) for upper 
genital tract infection as confirmed by endometrial biopsy.203 However, a 2009 review that 
included the PEACH 203 and 12 other studies, concluded that for women with clinical evidence 
of PID, the presence or absence of vaginal or cervical discharge was not helpful in making or 
excluding a PID diagnosis.272 Another analysis from the PEACH study assessed combinations 
of clinical features for supporting a PID diagnosis. In women with adnexal tenderness and an 
abnormal cervical-vaginal discharge, the probability of endometritis was only above 65% if 
the woman also had a positive chlamydia or gonorrhoea test result, or, if the woman also had 
an elevated temperature and an elevated leukocyte count.201 For the publication presented 
in Chapter 4, it is possible that some pathogen negative PID cases, particularly if evidence of 
vaginal inflammation was absent, were false positive diagnoses for  which the woman did not 
have PID or an STI.   
The microbial causes of PID are difficult to determine.  It is possible that some pathogen-
negative PID cases were associated with an STI that had cleared from the cervix but had 
ascended to the upper genital tract96 or with other bacteria, viruses or other micro-organisms 
that were not identified.99 Respiratory, enteric or novel bacteria and bacterial vaginosis 
associated pathogens have been identified in the upper genital tract of women with non-
gonococcal or non-chlamydial PID, although some of these pathogens have also been present 
in women without PID.2 96-99 PID is strongly associated with bacterial vaginosis.  Several studies 
have assessed specific bacterial vaginosis associated pathogens, reporting that women with 
high levels of Gram negative anaerobes in the lower genital tract are at higher risk of PID.97 
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166 177 Women with bacterial vaginosis are also at higher risk of incident chlamydia or 
gonorrhoea infection180 that could in turn increase their risk of ascending infection.  
Antimicrobial therapy for PID aims to cover the likely pathogens. The publication in Chapter 
4 provides evidence about the frequency of pathogens in a sample of Australian PID cases and 
this is information that has been infrequently reported.  Among the 330 PID cases, bacterial 
vaginosis was the most frequently diagnosed infection (21.5%), followed by chlamydia 
(18.8%), M. genitalium (4.5%) and gonorrhoea (2.4%).  Of 25 PID cases with more than one 
infection diagnosed, all but two were coinfected with bacterial vaginosis. Australian 
guidelines for PID management in primary care (Section 2.4.2) recommend cover for 
chlamydia, gonorrhoea and anaerobes as first line treatment with the addition of 
moxifloxacin if M. genitalium is diagnosed.216   
7.2.3 Summary  
In summary, the studies toward objective 1 provide updated evidence for the frequency of 
PID pathogens in Australia and new information based on the PAF.  Importantly, the PAF 
findings suggest that for a high chlamydia prevalence population that eliminating chlamydia 
might only reduce PID by 14%, and, that in a low chlamydia prevalence population that 
widespread chlamydia screening might only prevent a small number of PID cases.  The 
population level findings also suggest that chlamydia elimination might prevent a greater 
proportion of PID than gonorrhoea. At individual level, women with a gonorrhoea or 
chlamydia diagnosis were over three times more likely to be diagnosed with PID than women 
with no infection.  The pathogen-negative PID findings highlight uncertainties around PID 
diagnosis and aetiology and the need for biomarkers of upper genital tract inflammation that 
can improve certainty of a PID diagnosis.   
7.3 Objective 2 – To investigate time trends in PID diagnosis in an Australian sexual 
health clinic 
The third component of this thesis investigated PID diagnosis characteristics and time trends 
in a sexual health clinic, before and after clinical audit feedback.  The challenges in clinically 
diagnosing PID are well known. As noted in Chapter 5, an Australian sexual health clinic 
implemented actions toward improving consistency of PID diagnosis after a clinical audit 
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identified variability in PID diagnosis rates between doctors.  It was unknown whether PID 
diagnosis rates had altered following the audit response, leading to the analysis in Chapter 5.  
A manuscript of the findings is currently under review by the journal Sexual Health and is 
reproduced in full in Chapter 5.   
This was the first study to examine PID diagnosis time trends in an Australian sexual health 
clinic, showing that over a 14-year period the yearly PID diagnosis rate increased substantially 
from 0.8% to 2.9%. In the nine-year period following audit feedback the PID diagnosis rate 
increased by 8% yearly. However, after accounting for patient characteristics in the 
multivariable analysis this increase was no longer evident. As noted in Chapter 5, this finding 
appears to be influenced by substantial changes in the risk profile of patients assessed by 
doctors in the clinic and highlights the importance of adjustment for patient characteristics in 
interpreting time trends.   
Occurring around a decade ago, the PID focussed strategies in response to the audit included 
benchmarking and self-appraisal by doctors of their diagnostic criteria about whether they 
could be more sensitive to a PID diagnosis. Anecdotally some doctors considered these 
activities helped them to appraise their diagnostic criteria. The finding of less deviation in 
doctor-specific rates from overall PID rates after audit feedback suggests some change in 
clinical practice, although whether because of the audit is not known.  There is a risk that an 
emphasis on diagnostic sensitivity could compromise specificity, potentially delaying care for 
another condition.  Although the difficulties in PID diagnosis have led to assessments of the 
clinical criteria that best correlate with upper genital tract infection201 278 the minimum 
criteria of any one of cervical motion, uterine tenderness or adnexal tenderness as outlined 
in CDC guidelines remain the mainstay of PID diagnosis13 and further highlight the need for a 
simple non-invasive test that can accurately diagnose PID.  
Melbourne Sexual Health Centre is the only full-time and free sexual health service in the 
Australian state of Victoria and in response to increasing demand has implemented changes 
toward improving clinical efficiency.  As noted in Chapter 5, one internal change was 
implementation of a nurse express testing service273 that streamlined care for asymptomatic 
patients and increased capacity for more high risk symptomatic patients in the clinic. 
Externally, change to the required interval for screening sex-workers from three monthly279 
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also contributed to increased clinic capacity.280 In this context, doctors in this study undertook 
an increasing number of female consultations, including for high risk women and diagnosed 
many additional PID cases.  
The findings in Chapter 5 have implications for PID diagnosis in other clinical settings (such as 
general practice) that provide care for women with PID21 110 but where sexual health care is 
not core business.  Strategies toward improving PID diagnosis and management (see section 
2.4.3) have had only moderate success and the evidence base largely comes from hospital 
settings in the USA.46 47 222 223 For Australia, resources such as the PID checklist (described in 
Chapter 5) or an algorithm for assessing abdominal pain in women199 could be applicable to 
the general practice setting. However, the challenge is to systematise such resources into 
routine care, and, to provide education and training to support their uptake.  
In summary, it was uncertain whether PID specific actions after a clinical audit led to changes 
in PID diagnostic sensitivity.  Service improvements appeared to have had a greater impact 
on PID trends, providing additional capacity for high-risk patients and an increase in the 
overall number of PID cases diagnosed and managed.  
7.4 Objective 3 – To estimate time trends in PID diagnosis in Australian hospitals 
The final component of this thesis investigated yearly rates of PID diagnosis in Australian 
hospitals, the findings were published in Sexually Transmitted Infections274 and are 
reproduced in full in Chapter 6.  Although PID is the outcome of focus in this thesis, ectopic 
pregnancy rates were investigated in this publication as another measure of female 
reproductive tract morbidity.   
This study reported that in contrast to reported declines or static hospital admission rates of 
PID and ectopic pregnancy in Australia to around 200724 that rates between 2009 and 2014 
were no longer declining and increased in some instances. For example, admissions rates of 
chlamydial and to a lesser extent gonorrhoeal PID increased by 73%, unspecified PID by 9%, 
while chronic PID rates declined by 16%.  PID rates in emergency departments increased by 
34%.  Hospital admission and emergency department rates of PID showed a very different 
age-related pattern. Overall PID hospital admission rates varied little by age, whereas 
emergency department rates were substantially higher for younger than older women.  Most 
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PID cases were unspecified, for which the causes are unknown. Most STI-associated PID 
admissions were among younger women and most chronic PID admissions were among older 
women, which is consistent with other studies.14. Areas of residence that had greater socio-
economic disadvantage and were more remote also experienced higher PID rates. The ectopic 
pregnancy analysis showed higher rates among live births in 2009 compared with 2014 in 
admissions and emergency departments.  Although most ectopic pregnancy cases were 
admitted to hospital, an increasing proportion were managed without admission, consistent 
with increased use of non-surgical management for ectopic pregnancy in some areas.281   
As noted in Chapter 6, interpretation of these findings is not straightforward.  These results 
could represent changing sexual practices, increasing STI transmission and reinfections, 
changing healthcare usage or increased EP detection from improved diagnosis. The increasing 
admission rates for chlamydial, gonorrhoeal and unspecified PID and increasing PID rates in 
the emergency department could reflect a complex interplay of factors.  Case detection is an 
important component of Australian STI policy21 and surveillance data have shown recent 
increases in chlamydia and gonorrhoea rates for Australian women that have been attributed 
to increased testing and transmission.34 35 The increases in chlamydial and gonorrhoeal PID 
admissions could reflect increased testing or increasing awareness of PID as a provisional 
diagnosis for women with lower abdominal pain and a positive STI test.  Furthermore, in a 
context of increased testing and treatment of diagnosed infections, more women will be at 
subsequent risk of reinfection. As discussed earlier (Sections 2.2.1, 2.3, 2.7.1), chlamydia 
reinfection increases a woman’s risk of PID115 and high reinfection rates in Australia have been 
reported.265 Other factors associated with PID include M. genitalium, bacterial vaginosis and 
procedures involving uterine instrumentation,27 115 although the extent they have contributed 
to these findings is unknown.  It is unclear whether the admissions coded as chronic PID were 
for chronic pelvic pain as sequelae of PID or another chronic pelvic inflammatory condition. 
Most chronic pelvic inflammatory conditions were coded as chronic salpingitis or oophoritis, 
suggesting they were sequelae of an earlier infection.  The decline in chronic PID admissions 




The increasing rates of PID diagnosis in emergency departments are a cause for concern, 
particularly given that over two-thirds were managed without admission.  Australian 
guidelines recommend out-patient management for mild to moderate PID,200 that includes 
general practice.  The reasons these women attended an emergency department are not 
known, but it is possible that many were suitable for management in general practice.  Work-
force shortages particularly in non-metropolitan areas,275 and out-of-pocket expenses 
incurred when attending general practice 232 276 could adversely impact on a woman’s ability 
to access general practice for timely and affordable sexual health care, thereby placing them 
at increased risk of an STI ascending to the upper genital tract, and, influencing them to attend 
the emergency department for mild to moderate PID instead.  These findings could also 
reflect inadequacies in PID diagnosis and management48 217 and STI care in general practice.  
Recent STI policy in Australia, has had a strong focus on testing coverage.  The PID and ectopic 
pregnancy rates presented in this study provide valuable information about the epidemiology 
and healthcare usage for these conditions, showing that PID and ectopic pregnancy remain 
important causes of hospital admission for STI-associated complications among women of 
reproductive age.  Inclusion of emergency department data provided new information about 
PID diagnosis in Australia showing that emergency departments provide care for many 
additional PID cases, particularly for young women, warranting a strengthened focus on 
reducing the risks of these sequelae. However primary care data are needed for a more 
complete picture of PID epidemiology and healthcare use, particularly given different 
patterns between hospital admissions and emergency department attendances. 
There is no ongoing mechanism for monitoring PID incidence in Australia.  The challenges in 
measuring PID and ectopic pregnancy rates in this ecological analysis of routinely collected 
data highlight the need for improved data sources and surveillance that include hospital and 
primary care data to facilitate comparable measures over time. Data linkage has been used 
to quantify the risk of a PID hospitalisation following a chlamydia or gonorrhoea diagnosis41 
and could facilitate measurement of the temporal relationship between STIs and 
complications, including the risk of PID following repeat infection.  In view of unchanging 
chlamydia prevalence despite increases in testing115 254 and high rates of chlamydia 
reinfection,22 192 improving case management has been a focus of recent debate about 
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chlamydia and STI control.115 In particular the need for methods to improve partner 
notification to reduce onward transmission and reinfections, and, retesting to detect repeat 
infections early are identified.  The impact of such measures on PID should also be monitored.  
In summary, the study toward objective 3 showed that PID remains a substantial reproductive 
health issue for young women in Australia and an important burden on the healthcare system.  
While overall hospital admission rates remained steady between 2009 and 2014, the analysis 
of hospital data found that chlamydial or gonorrhoeal PID comprised a small but increasing 
proportion of PID admissions and chronic PID rates declined.  PID rates were consistently 
higher for younger women suggesting an STI aetiology even if an STI was not confirmed. Areas 
of residence that had greater socio-economic disadvantage and were more remote also 
experienced higher PID rates. Considering systems for monitoring PID incidence are limited, 
this study shows how ecological analyses of data from health settings where women with PID 
are managed can be used to measure PID trends.   
7.5 Challenges  
There remain several challenges with understanding diagnosis and managing PID. Broadly 
these challenges can be viewed as relating to PID aetiology and diagnosis, issues related to 
availability of data to investigate PID epidemiology, and analytical challenges.  
7.5.1 Challenges posed by PID aetiology and diagnosis  
First and foremost, is that clinical diagnosis of PID is imprecise and there is no non-invasive 
and objective test for its diagnosis.  Therefore, for studies involving PID as an outcome, there 
is uncertainty about the precision of estimated trends and associations.4 22 205 Related to this 
is that the natural history of many STIs and their relationship to PID and more distant 
outcomes is not fully understood.  While prevention of infertility or other outcomes such as 
ectopic pregnancy is an important rationale for STI control policies,21 22 PID is often used as 
an interim measure of STI morbidity because the timeframes to sequelae such as infertility 
are longer and may not be recognised until affected women try to conceive. Despite these 
challenges, epidemiological and ecological studies analysing routinely collected data provide 
much of the knowledge about PID incidence and its relationship with STIs.  As in this Thesis, 
it is important that they are robustly conducted but cautiously interpreted to provide current 
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and updated information about PID and STIs.  This issue reinforces the need for objective non-
invasive diagnostic biomarkers for PID that can not only improve precision of PID diagnosis to 
benefit individual patients but will improve precision of clinical and epidemiological studies 
assessing PID.  
7.5.2 Challenges posed by routinely collected data sources for data measuring PID  
A second challenge was the availability and usefulness of routinely collected data to answer 
questions about PID.  This thesis analysed data from two routinely collected sources, each 
with strengths and limitations for answering questions about PID.    
Sexual health clinics in Australia are a key primary care setting for patients at high sexual risk 
to access specialist care.  Data were obtained from Melbourne Sexual Health Centre, the state 
of Victoria’s only free full time sexual health service servicing a state population of over 6 
million.  The clinic has a well-established electronic clinical record system that collects 
demographic and risk behaviour data from all new patients then at three-monthly intervals 
for repeated visits. This electronic record also collects clinical data (STI tests, diagnoses) that 
are easily extracted (and deidentified as required) for epidemiological analyses such as 
investigating the microbial associations of PID.  However, for female non-sex worker patients, 
repeat visits are generally limited to four weeks after the first visit.  This meant it was not 
possible to assess long-term temporal relationships between STIs and sequelae for individual 
women. To maximise data completeness, cross-sectional analyses of a woman’s first episode 
of care were conducted.  This provided a large sample size with complete case data for over 
15000 women.  Another limitation of these sexual clinic data was how the variable classifying 
women as symptomatic or asymptomatic was derived. As noted in the three studies analysing 
these data, clinic attendees are asked to report any presenting symptoms at triage.  It is 
possible that some female patients who did not report symptoms at triage, subsequently 
reported symptoms suggestive of PID to the clinician during the history taking and clinical 
examination.  If this occurred, there would be some inaccuracy in the symptoms at triage 
variable, in which some women that later reported symptoms were classified as 
asymptomatic.   
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In Australia, hospital admission data systems are managed at a State level and collect data for 
all hospitalisations at public and private hospitals with diagnoses codes based on  
International Classification of Diseases (ICD-10) codes282 assigned by trained coders.  
Emergency department data systems are also managed at State level and collect data about 
presentations to public hospitals with a designated emergency department237 Data reporting 
from emergency departments is voluntary, and diagnosis codes are assigned by clinicians, 
making emergency department data more variable than admissions data. Diagnosis codes in 
emergency departments were based on ICD10, ICD9 or Systematized Nomenclature of 
Medicine (SNOMED) codes.283  Due to these differences in data systems there were many 
challenges in constructing a dataset for analyses of PID and ectopic pregnancy rates. 
Approvals were required from State departments of health in Victoria, NSW and Queensland 
before data from six separate data systems could be extracted, validated, and re-extracted (if 
indicated). Extensive formatting and cleaning was involved to combine these data into a 
separate dataset for hospital admissions and emergency department presentations.  Because 
the analysis focussed on trends, emergency department data were only included if they arose 
from hospitals that contributed data for the entire study period and if there was low 
variability in the annual number of presentations.  These challenges in constructing a dataset 
for investigation of PID diagnosis trends, again highlights the need for improved data sources 
and surveillance that facilitates comparable measures over time.   
7.5.3 Analytical challenges  
The main analytical challenges in this research is related to missing data, and, that at 
residential postcode level, PID can be a relatively infrequent outcome.  
In the sexual health clinic dataset for investigation of the PAF of PID associated with chlamydia 
or gonorrhoea there were 18,586 women eligible for the study. Complete case data were 
available for 15690 chlamydia tested women, and, a subset who were also tested for 
gonorrhoea (n=8839).  To assess the impact of missing data a sensitivity analysis using 
multiple imputation was conducted, and the odds ratios from the univariable and 
multivariable logistic regression models for the complete case analysis were compared with 
those derived from the multiple imputation models.  A description of the two imputation 
models and their results were published as supplementary information to the publication in 
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Chapter 3. The estimated adjusted odds ratios for PID from the complete case analysis for 
chlamydia-tested women, chlamydia + gonorrhoea-tested women and multiple imputation 
were very similar in this analysis. 
In the hospital dataset for assessment of yearly rates of PID, the admissions and emergency 
department data were analysed at the level of residential postcode using population 
denominators.  Across 1678 postcodes in three states, around one fifth had no PID cases 
recorded in the hospital admission or emergency department data. In consideration that 
there were large numbers of postcodes with no cases, zero inflated Poisson regression was 
used to assess variation in yearly rates.  The fit of the zero-inflated Poisson models was 
compared to ordinary Poisson models using the Vuong test. 
7.6 Ethical considerations 
The main ethical considerations in this PhD are related to privacy, sensitive information 
related to STIs and PID, and age.  Privacy of individual patients was protected as follows:  no 
direct contact was made with any patient; all patient data came from secondary sources and 
reflects routine clinical care; all data files were stored on password protected secure servers; 
and all reporting was at aggregate level so that no sensitive information was potentially 
identifiable to any one individual.   All studies only considered patients aged 15 years or over. 
7.7 Implications for practice, policy, and research 
This thesis has sought to provide updated evidence about the epidemiology of PID diagnosed 
in Australia, particularly with reference to chlamydia infection. Based on quantitative analyses 
of routinely collected sexual health clinic and hospital data, I have investigated the risk of PID 
associated with chlamydia and gonorrhoea infection; the microbial characteristics of PID 
cases including pathogen negative PID; PID diagnosis characteristics and trends in a sexual 
health clinic; and how much PID is diagnosed in Australian hospitals over time.  The findings 
have implications for clinical practice, STI control policies, and future research.  
7.7.1 Implications for clinical practice  
Chlamydia and gonorrhoea are well established PID pathogens (Section 2.2). The study in 
Chapter 3 found that the risk of a PID diagnosis was 4.4-fold and 3-fold higher for women 
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testing positive for gonorrhoea or chlamydia respectively than for woman testing negative for 
these infections. This information can inform the clinical discussion and assessment. Women 
diagnosed with chlamydia or gonorrhoea should be advised that these infections can cause 
PID and that they should return for review should symptoms such as pelvic pain or 
dyspareunia develop.  This advice also applies for women diagnosed with M. genitalium 
infection. This knowledge of individual PID risk could also remind clinicians when prescribing 
STI treatment to assess for presence of symptoms such as pelvic pain, abnormal discharge or 
dyspareunia that suggest PID.  In addition, PID should be considered as a differential diagnosis 
for any young women at STI risk and presenting with low abdominal pain.   
The study in Chapter 4 found that chlamydia or bacterial vaginosis were the most commonly 
identified infections in women with clinically diagnosed PID, followed by M. genitalium, and 
gonorrhoea.  Australian guidelines are consistent with these findings, recommending 
antibiotic cover for chlamydia, gonorrhoea and anaerobes as first line treatment, with the 
addition of cover for M. genitalium if diagnosed.216 Although chlamydial PID was more 
common that gonorrhoeal PID, recent increases in heterosexually transmitted gonorrhoea in 
Australia34 35 could impact on the frequency of gonorrhoeal PID diagnosed in primary care and 
hospital settings. In Australia and internationally there is growing concern about the reduced 
susceptibility of gonorrhoea to ceftriaxone, so continuing surveillance is essential to inform 
treatment guidelines.21 110 
The study in Chapter 4 illustrates the uncertainties about PID diagnosis and aetiology, finding 
that almost two thirds of PID cases had no pathogen identified. Although some of the 
pathogen-negative PID cases may have been false positives, this is consistent with minimum 
criteria that recommend a low threshold for a PID diagnosis.13  The difficulties in diagnosing 
PID and the frequent lack of association with a causative organism further highlight the need 
for biomarkers of upper genital tract inflammation that can improve certainty of a PID 
diagnosis. Until we have well-validated rapid biomarkers that improve precision of clinical PID 
diagnosis, the basis for PID diagnosis and treatment should continue to be based on clinical 
features and sexual risk rather than microbiological findings. 
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7.7.2 Implications for STI control 
STI control involves a range of primary and secondary prevention activities that seek to reduce 
the incidence of STIs and their associated morbidities, including PID and other adverse female 
reproductive impacts (Section 2.7).21 139 248  Knowledge of the attribution of STIs to PID can 
provide policy makers with information about where to target control activities and their 
potential impact.   
The PAF analysis in Chapter 3 provided a measure of how much PID might be avoided if 
chlamydia or gonorrhoea were eliminated from a population.  The key finding was that for a 
high chlamydia prevalence clinic population, eliminating a current chlamydia infection might 
at most reduce PID by 14% whereas gonorrhoea elimination might only reduce PID by about 
1% reflecting the low gonorrhoea prevalence in the study population. Although as noted 
earlier, recent increases in heterosexual transmission of gonorrhoea35 could translate into a 
higher proportion of PID cases being gonorrhoeal associated.  
Over the past two decades STI and chlamydia control actions in Australia and other high-
income countries have had a strong focus on testing coverage to detect asymptomatic 
infections, with chlamydia screening debated as an intervention that might reduce 
transmission and complications.21 257 258 284-286 If Australia were to implement an organised 
screening programme, the main setting would be general practice, being where most 
chlamydia testing and diagnosis occurs. Given that asymptomatic presentation maybe more 
common for women attending general practices than sexual health clinics, the study in 
Chapter 3 also reported the PAF of PID associated with chlamydia for asymptomatic women. 
The findings suggested that chlamydia elimination in a low prevalence setting might only 
prevent a small number of PID cases.  If considered in the context of the ACCEPt study that 
found it was not possible to reduce chlamydia prevalence in the population with achievable 
levels of annual testing,256 and a UK cost analysis that reported over £4 million in chlamydia 
screening costs to prevent around 400 PID cases,263 the costs of PID prevention via chlamydia 
screening in general practice could be substantial (Section 2.7.1).  Recent debate about 
chlamydia and STI control has seen some countries shift to an increased focus on improving 
case management to reduce the risk of reinfections and complications.23 115 248  
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An important finding reported in Chapter 6 was that PID diagnosis rates increased in hospital 
emergency departments between 2009 and 2014, and, that over two-thirds of PID in the 
emergency department was managed without admission. The reasons these women 
attended an emergency department are not known, but it is possible that many were suitable 
for management in general practice.  This finding could reflect inequitable access to general 
practice for reasons such as out-of-pocket expenses232 276 or low availability of timely 
appointments287 and inadequacies in STI and PID diagnosis and management in primary 
care.48 217 Other Australian evidence shows sub-optimal rates of partner notification and 
retesting after chlamydia treatment in general practice264 that can increase the risk PID.  
There is a clear need for strengthening STI case management in the primary care sector that 
prioritises effective partner notification to prevent reinfection, timely re-testing after 
treatment to detect re-infection earlier and to reduce complications.  The need for new or 
improved care models in primary care to enhance STI management and their complications 
is identified in Australian policy21 and will be explored in a research project for implementing 
an integrated chlamydia management program in general practice.288 
7.7.3 Measuring PID trends  
Although this research has provided a measure of recent PID time trends in hospital, it is 
difficult to directly compare the findings to other standalone studies conducted in different 
countries, settings or time periods.  The need to develop indicators for monitoring STI-related 
morbidity has been identified in Australian policy21 and in international guidance regarding 
chlamydia control.115 The Australian state of NSW has recently developed an indicator of 
chlamydia morbidity via data linkage of chlamydia notifications and PID hospital admissions 
for its STI strategy.289  Although useful, this indicator only measures chlamydia associated PID 
cases that are severe enough to require hospital admission.  The analysis of emergency 
department data274 and other analyses 228 have shown that a large burden of PID is managed 
without admission.    
Some other suggestions for monitoring PID are provided here.  As noted earlier (Section 7.4), 
there is a need for improved data sources and surveillance that includes data from health 
settings that PID cases are managed (hospital admission, emergency departments, primary 
care) to facilitate comparable measures of PID over time. In view of recent increases in 
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gonorrhoea diagnoses among Australian women34 35 and the increased risk of PID 
hospitalisation following a gonorrhoea infection,41 consideration of gonorrhoea and 
chlamydia in indicators of PID is imperative. Such systems could involve data linkage to 
facilitate measurement of the temporal relationship between STIs and complications, and, to 
assess patterns in health care usage, for example rates of admissions from primary care or 
the emergency department.  PID cases represented in hospital inpatient and emergency 
department data could be categorised using ICD10 codes to provide a measure of STI-
associated PID, unspecified PID and chronic PID.  An overall measure of PID incidence could 
be determined by the addition of non-admitted emergency department cases and cases 
managed in primary care to the number of cases in managed as inpatients, using population 
denominators.  Alternatively, sentinel surveillance for PID could involve collection and 
analysis of data from selected emergency departments, hospitals, and primary care clinics 
(sexual health, women’s health clinics, general practice).   
7.7.4 Improving PID diagnosis  
This PhD research has highlighted the need for an evidence base regarding resources and 
processes that can support improvements in PID diagnosis and management in the Australian 
context.  The study of PID diagnosis trends in the sexual health clinic (Chapter 5) showed that 
service improvements created extra capacity for the number of high-risk patients and PID 
cases diagnosed, but it was uncertain whether PID specific actions after a clinical audit led to 
changes in PID diagnostic sensitivity.  In addition, the study of PID rates in hospitals (Chapter 
6) showed increasing PID rates in emergency departments that could reflect issues in access 
and/or inadequacies in PID diagnosis and management in general practice clinics.  Given that 
general practice is Australia’s mainstream primary care setting where many women with STIs 
or mild to moderate PID are likely to present, it is imperative this sector is resourced with the 
tools and activities to provide best practice STI and PID care. 
Toward this objective, Australian policy identifies the need for innovative models of care that 
support timely and appropriate referral between primary healthcare and specialist services, 
and, that incorporate interventions shown to be effective in improving treatment and 
management.21 250 Some examples of interventions that have been evaluated in specialist 
settings include partner notification websites266 and promotion of retesting for STIs after an 
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earlier positive test via SMS reminders and mailed specimen kits.267 However their feasibility 
and impact in the general practice setting is not known.  For PID, the checklist developed by 
MSHC (Chapter 5) and a decision tree for assessment of low abdominal pain in women of 
reproductive age and possible differential diagnosis199 were developed with an  objective to 
support decision making for a PID diagnosis.  Again, their impact in general practice is 
unknown.  Assessment of the feasibility and impact of these resources toward improving PID 
diagnosis and management should be accompanied by workforce training and educational 
resources to integrate them into routine general practice care.   
7.8 Conclusions  
This thesis provided the first Australian estimates of the population level risk of PID associated 
with chlamydia and gonorrhoea. This new information based on the PAF suggests that 
eliminating chlamydia in a high prevalence population might only reduce PID by 14% and 
around 1% if gonorrhoea were eliminated, and, further for low chlamydia prevalence 
populations, that only a small number of PID cases might be avoided by widespread screening.    
Updated evidence was provided for the frequency of PID pathogens in Australia, and, the 
need for non-invasive bio-markers for upper genital tract inflammation was highlighted by 
the many cases without an identified pathogen.  In the absence of bio-markers the decision 
to commence PID treatment should continue to be based on clinical features and sexual risk.  
This thesis found that PID remains a substantial cause of attendances at sexual health clinics 
and hospitalisations for reproductive related health issues for women in Australia. Analyses 
of sexual health clinic data demonstrated the importance of adjustment for patient 
characteristics in interpreting time trends, and, investigation of hospital data showed how 
ecological analyses of data from health settings where women with PID are managed can be 
used to measure PID trends.  Evidence was provided for an increase in PID diagnosed in 
Australian emergency departments that could reflect increasing PID incidence, shifting 
healthcare usage from primary care, or, inadequacies in PID diagnosis and management in 
primary care.   Primary care data and systems to monitor PID incidence are needed to better 
understand PID epidemiology, healthcare usage, and the impact of chlamydia and STI control 
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Appendix 1 Supplementary online material for the publication in Chapter 3 
Appendix 1 provides additional material that was published online only at 
http://dx.doi.org/10.1136/sextrans-2015-052195 with the publication that is reproduced in 
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Appendix 2 provides additional material that was published online only at 
http://dx.doi.org/10.1136/sextrans-2017-053423 with the publication that is reproduced in 
Chapter 6.  
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